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ABSTRACT
This thesis has explored the use of pulmonary function tests, sleep studies, 
volitional and nonvolitional respiratory muscle strength assessment techniques 
in the evaluation of patients with neuromuscular diseases. I have particularly 
concentrated on patients with myotonic dystrophy and motor neurone disease, 
which comprised the largest group of patients apart from Duchenne muscular 
dystrophy, referred for assessment to Glasgow Respiratory units with expertise 
in non-invasive ventilation.
In a group of 20 myotonic dystrophy (MyD) and 5 subjects with MND, I went 
on to establish that spirometry remains a useful basic tool. Supplemented with 
mouth pressures, we can derive useful information regarding global respiratory 
muscle strength. Additional routine evaluation of static lung volumes and 
diffusion capacity did not add in useful information that would be useful in 
routine clinical care.
It is well known that sleep worsens respiratory failure. The use of screening 
sleep studies in assessing patients with neuromuscular diseases remains 
debatable. 25 subjects with MyD and 12 with MND were studied. Routine 
sleep studies did not seem to add any useful information that could not be 
predicted from the daytime pulmonary function tests apart from 12% of MyD 
patients where it was useful in identifying nocturnal respiratory disturbance.
vil
However it is debatable whether treating these abnormalities affects prognosis 
in the long term.
There has been significant contiibution to our understanding of respiratory 
muscle strength in various circumstances such as in children and intensive care 
setting with the introduction of magnetic phrenic nerve stimulation teclmique. 
After establishing the methodology at the laboratory, in a group of 10 patients 
with myotonic dystiophy, we found this to be useful in providing nonvolitional 
diaphragm strength. It would be immensely useful in this group as mouth 
pressures are frequently reduced due to facial muscle weakness. We showed 
that underestimation of respiratory muscle strength using volitional methods is 
common in MyD [Mean (sd) Sniff Pdi of 67.1(30.7)cm H2O vs bilateral Tw Pdi 
of 17.1(9.4) cm H2O]. BAMPS was also a useful daytime marker of nocturnal 
respiratory disturbances and low Tw Pdi identified 75% (3 out of 4) subjects 
with sleep related breathing disorder during daytime. Repeat volitional and 
nonvolitional tests 4-6 months’ apart confmned stable respiratory muscle 
strength.
Lastly, I studied patients with motor neurone disease. This group had severe 
respiratory muscle weakness even at the outset with marked symptoms. Non- 
invasive ventilation improved symptoms in its users. Interestingly, we found 
that the inspiratory and expiratory positive airway pressures required for these 
patients were significantly lower compared to patients with hypoventilation due 
to obesity and post-polio syndromes.
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CHAPTER I
INTRODUCTION
1.1 CONTROL OF VENTILATION
Ventilation is an essential aspect of life and depends primarily on O2 consumption and 
CO2 production within the tissues. It is normally controlled by a combination of central 
rhythm generator, mechanical and chemical stimuli with input from higher central 
nervous system stmctures (1). Both involuntary and automatic/voluntary controls operate 
in humans. Other main components of the respiratory system include the lungs and the 
respiratory pump comprising of respiratory muscles and chest wall. This thesis has 
explored the methods used to assess respiratory muscles in nonnal people and subjects 
with neuromuscular disorders, particularly those with myotonic dystrophy (MyD) motor 
neurone disease (MND)
HIGHER CORTICAL CENTRES:
Electrical stimulation of many cortical areas (especially limbic area) in animals has 
revealed them to be inhibitory to ventilation. However certain motor and pre-motor areas 
are excitatory (1). Cortical impulses interact with medullary neuronal network as well as 
spinal cord via corticobulbar and corticospinal tracts respectively.
CENTRAL RHYTHM GENERATOR (fig 1.1.1):
The central rhythm generator controls the rate and depth of breathing with feedback from 
peripheral counterparts. Respiration is initiated by a complex interaction of neuronal 
aggregates in medulla and pons. The medulla contains two dense bilateral neuronal 
aggregations -  i) Dorsal respiratory group (DRG) neurones situated in the dorsomedial 
medulla, in association with the ventrolateral nucleus of the solitary tract. These
neurones are predominantly inspiratory in nature and interact with the ventral group via 
the collaterals.
ii) Ventral respiratory group (VRG) neurones lie in the ventrolateral medulla in 
association with reti’ofacial nucleus, nucleus ambiguous and nucleus retroambigualis. 
Neurones in association with retrofacial nucleus are mostly expiratory and form a group 
called ‘Botzinger complex’ that has been shown to inhibit few DRG neurones and 
plirenic motor neurones. The neuronal output from both these groups is carried in the 
ventral and dorsal columns of the spinal cord to phrenic and intercostal motor neurones 
and thereby to diaphragm and intercostal muscles. Commonly known pneumotaxic 
centre is located in the dorsolateral pons in association with nucleus parabrachialis 
medialis and this region is thought to play an important role in switching between the 
inspiratory and expiratory phases of respiration. Lumsden described the rostro-caudal 
organisation of the mammalian neural network in an anaesthetised cat back in 1923 (2). 
He was also the first to coin the term ‘apneusis’ that represented prolonged inspirations 
approaching spasms along with brief expiratory efforts after combined bilateral vagotomy 
and pneumotaxic centre lesion. The brainstem centres predominantly control automatic 
respiration.
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Fig 1.1.1: Pontine, medullary and spinal cord respiratory neuronal aggregations 
schematically depicted from a dorsal view (right) of the brain stem and spinal cord. Also 
shown (left) are transverse sections of the medulla at the corresponding levels indicated 
by the solid and dashed lines on the right. C = complex; DRG = dorsal respiratory group; 
IX = 9*^’^ (glossopharyngeal) cranial nerve; iiA = nucleus ambiguus; nRA = nucleus 
retroambigualis; iiTS = nucleus of the tractus solitarius; nXII = (hypoglossal) cranial 
neiwe nucleus; PRG = pontine respiratory group; RVLM = rostral ventrolateral medulla; 
VRG = ventral respiratory group; X = 10^ '^  (vagus) cranial nerve. (Reproduced and 
modifred with permission from Duffin J, Ezure K, Lipski J. Breathing rhytlim generation: 
Focus on the rostral ventrolateral medulla. News in Physiol Sci 1995;10:133-140).
GENETIC INFLUENCES:
Recent studies have identified molecular switches that operate at early embryonic stages 
to develop brainstem respiratory rhythm generator (3). This has been demonstrated in 
chick embryos. Most of these studies are still in infancy but the gene microarrays and 
proteomics now used to address cell signalling are likely to shed more light (3).
NEUROMECHANICAL INPUT:
Although resting alveolar ventilation is predominantly set by chemical stimuli, 
mechanoneural receptors can modify ventilatory pattern. Their exact role especially the 
relation between structure and function in humans is yet to be defined. The receptors 
known to-date include (4-6):
i) SLOWLY ADAPTING PULMONARY STRETCH RECEPTORS (SAR) 
-  are located in close proximity to the smooth muscle cells of both extra and 
intrathoracic lower airways with vagal afférents. They are stimulated by 
increase in the lung volume. For instance if the lung volume is held at end 
inspiratory level, a reduction in respiratory rate occurs predominantly by 
prolongation of the expiratory phase [Inflation reflex of Hering Breuer -  first 
described in 1868 (7)]. This reflex is apparent in newborns and adults under 
general anaesthesia when tidal volumes over 800ml are used. A reduction in 
the activity of these receptors with lung deflation stimulates inspiratory onset 
(Deflation reflex). This may contribute to the tachypnoea that occurs in 
atelectasis.
ii) RAPIDLY ADAPTING PULMONARY STRETCH RECEPTORS 
(RAR/Irritant receptors) -  are concentrated near the carina and central 
bronchi, also with vagal afferents. They are fewer in number compared to 
SARs and are associated with airway epithelium. Mechanical or chemical 
stimulation (with histamine or prostaglandins) of RAR generates cough reflex 
(8).
iii) C-FIBER ENDINGS -  are attached to umnyelinated vagal afferent fibres and 
are found close to the pulmonary capillaries [where they are called type J 
(juxtapulmonary eapillary) receptors (9), first described by Paintal in 1969] 
and the bronchi in proximity to bronchial circulation. They are stimulated by 
endogenously produced substances (10) such as histamine, prostaglandins, 
bradykinin, serotonin and may have a role in astlnna, pulmonaiy venous 
congestion and pulmonary embolism (10). They are also stimulated by lung 
hyperinflation.
iv) NEUROEPITHELIAL BODIES -  situated at the bifurcation of small 
bronchi are thought to act as sensors of hypoxia and thereby increase 
ventilation (11).
CHEMICAL CONTROL OF BREATHING:
Breathing can be altered by variation in blood chemistry. The peripheral 
chemoreceptors are located in the aortic and carotid bodies. The aortic bodies lie near 
the aortic arch and carotid bodies close to the carotid bifurcation on either side of the 
neck. Aortic bodies, though active in infancy and childliood, are relatively dormant in 
adulthood (12). The carotid bodies consist of two kinds of cells -  type I/glomus/chief 
cells that sense hypoxia and type Il/sheath/sustentacular cells, their function being 
uncertain. The sensory neiwe endings from carotid bodies join the sensory fibres of 
carotid baroreceptors to form the carotid sinus nerve, the cell bodies of which lie in the
7petrosal sensory ganglion of the glossopharyngeal nerve. They also contain autonomic 
neives to regulate blood flow. The main neurotransmitter released in response to hypoxia 
is dopamine although other neurotransmitters have been implicated. Afferent input from 
these receptors leads to the release of the excitatory amino acid glutamate centrally (13) 
that increases ventilation. The peripheral chemoreceptors are complex sensors receiving 
high blood flow relative to their size and respond to changes in both arterial pH and 
partial pressure of oxygen (PaOz). Hypoxia and acidity interact and are more than 
additive in their combined influence to increase the chemoreceptor discharge and thereby 
ventilation. The partial pressure of carbon dioxide (PaC0 2 ) also stimulates these 
chemoreceptors, though to a lesser extent, but can have an effect due to its influence on 
pH. Deneiwation of the peripheral chemoreeeptors leads to 12-20% reduction in 
ventilation and the PaCO] increases by 5-lOinm Hg [0.7-1.3 kPa] (14). The central 
chemoreceptors located near the ventrolateral surface of the medulla oblongata sense H^ 
concentration in the local enviromnent. The ventilatory response to acute rise in PaC0 2  is 
predominantly due to central chemoreceptors. CO2 increases the H^ concentration in the 
extracellular fluid that bathes the chemoreceptors. Small alteration in H^ concentration 
within the brain interstitial fluid leads to marked changes in the ventilation. For the same 
arterial pH change, rise in ventilation is greater for respiratory acidosis than that due to 
metabolic origin, as the blood brain baixier is more permeable to CO2 compared to HCO3 ' 
due to its lipid solubility (15) and hence the effect of respiratory acid-base disturbance is 
much more immediate. The stimulatory effect of hypercapnia is offset by compensatory 
renal retention of bicarbonate and a concomitant increase in ECF and CSF bicarbonate, 
which buffer hydrogen ions. This takes 48-72 hours to develop.
The cholinergic activity of the respiratory neurones is high with central acidosis, the 
effect being exerted via the muscarinic - Ml and M3 receptors and it has been shown that 
increased ventilation due to salicylates is a function of this cholinergic system (16). Beta- 
adrenergic agents also have stimulatory effect on central ventilation. On the other hand, 
alpha-adrenergic agents inhibit the cholinergic system and thereby reduce ventilation 
(17).
The central rhythm generator and the sensors act on respiratory muscles, the effectors to 
move air in and out of the lungs. Fig 1.1.2 schematically summarises the control of 
breathing at the different levels involved.
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Fig 1.1.2: Schematic Representation - Control of Breathing.
VENTILATORY DRIVE:
The ventilatory drive measures the response in ventilation per minute. A major drawback 
to the methods used to measure drive is that they depend on normal lungs, respiratory 
muscles and chest wall mechanics. The commonly used methods include Hypoxic and 
Hypercapnie Ventilatory Responses. In the physiological range of PaCO], the minute 
ventilation rises linearly with rise in PaCOz. The slope of this line is normally 2-5 
L/min/mmHg PaCOz [15-37.5 L/min/kPa PaCOz (fig 1.1.3)]. A reduced slope indicates 
decreased ventilatory drive. About 15% of the population have reduced response to CO2 
with ventilation increasing by only 1 L/min/mmHg PaCOz- They are at increased risk of 
ventilatory failure in the presence of additional burdens to the respiratory system such as 
obesity and clironic obstructive lung disease (18,19,20).
The change in ventilation to falling Pa02 follows a hyperbolic cuiwe (fig 1.1.4). On the 
other hand, if plotted against oxygen saturation this remains a linear relationship. 
Hypoxic ventilatory response largely assesses the integrity of peripheral chemoreceptors 
with some evaluation of the central input. Ventilation increases sharply once PaOz is less 
than 60 mm Hg (8 kPa). Since hypoxic drive is rather modest when Pa02 > 60 mm Hg, it 
is generally the carbon dioxide response that maintains normal ventilation at sea level. 
Once PaOz is about 40mm Hg (5.3kPa), ventilation increases to 3-6 times the resting 
value. In patients who have depressed hypoxic drive, invariably some reduction in 
hypercapnie ventilatory response will be noted. Genetic influences, age, anaesthetic 
agents and sedatives all affect the range of measured ventilation (21,22).
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Fig 1.1.3: Ventilatory response to inhaled CO2 at two different levels of alveolar partial 
pressure of oxygen (PAO2). The slope increases with additional low PAO2 . Modified 
and reproduced with permission from Harcourt Publishers Ltd.- ‘Comprehensive 
Respiratory Medicine’- Albert, Spiro, Jett eds 2001 - Section 1: Structure and Function -  
Culver B H.
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P A C 02= 42 mm Hg=5.5kPa.1 0- Not isocapnic
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PACO2 =  48mmHg — - PACOg =  42mmHg —— Not isocapnic
Fig 1.1.4: Hypoxic Ventilatory Response. Non-linear increase in ventilation in response 
to reduced PAO2 . Response is enhanced in presence of hypercapnia. Modified and 
reproduced with permission from Harcourt Publishers Ltd.- ‘Comprehensive Respiratory 
Medicine’- Albeit, Spiro, Jett eds 2001 - Section 1: Structure and Function -  Culver B H.
An attempt to measure the drive in patients with lung or chest wall disease has led to the 
development of Po.i technique. This is an inspiratory pressure developed against a
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transiently closed shutter during the first 100 msec of a tidal breath. It has been suggested 
that within this time, mechanical status of the respiratory system does not influence the 
force generation and the occlusion is too short to alter respiration voluntarily (23). Po.i 
technique can also be used to assess ventilatory response to hypoxia and hypercapnia. 
The accuracy of this technique needs to be established as there is significant overlap 
between normal subjects and patients with lung disease but VE/Pq.i (the ratio of resting 
ventilation to mouth occlusion pressure ie., output/input) has been shown to be a valid 
discriminator between normal and disease states (24). However, some people may find 
the occlusion uncomfortable and maximal rate of change of oesophageal pressure 
(APoes/At) over 100ms of inspiration will give another measure of central respiratory 
drive (25).
In absence of serious mechanical impediment to ventilation, PaCOi level above the 
normal range (37-43mmHg or 4.9-5.7kPa) at sea level in itself reflects low respiratory 
drive.
Electro myogram (EMG) studies of respiratory muscles: The slope of moving time 
average of the diaphragm EMG is a reliable measure of neural inspiratory drive (26). 
However diaphragm EMG response to CO2 rebreathing does not increase as much as Pq.i. 
This may be due to recruitment of intercostal muscles or enlianced contractility of the 
diapliragm itself in presence of increased load (27).
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In conclusion, a given ventilatory drive for a subject should be inteipreted in the context 
of the integiity of lungs, chest wall and respiratory muscles.
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1.2 SLEEP AND RESPIRATION
To sleep; perchance to dream: ay, there is the rub - William Shakespeare
(Hamlet III, i, 65-68)
Haldane in 1905 noted that breathing ceased altogether if PaC02 level was extremely low 
and there was no need to breathe (28). But Fink et al in 1963 observed this to be tme 
only if the subject was asleep or anaesthetised but not if awake (29). This has given 
origin to the so called ‘wakefulness drive’ although the exact nature and location of this 
stimulus remains unclear.
Many changes occur during sleep. For instance, there is reduced metabolism by 10-25% 
with decreased oxygen consumption; hormonal secretory patterns change and body 
temperature decreases. Most are functions of the brain tissue, thought to be restorative in 
nature, but still there are some features that associate respiration and sleep in a unique 
way.
RESPIRATORY DRIVE:
There is functional overlap between the neurones that regulate sleep and those that 
control respiration. Also, sleep related breathing disorders (SRBD) arise from sleep- 
dependent changes and this is supported by the fact that most people with SRBD tend to 
have normal breathing whilst awake, at least in the initial stages of the disease. Eucapnic 
hypoxic ventilatory response is reduced both in noimal males and females and in both 
non rapid eye movement (NREM) and rapid eye movement (REM) sleep (30). Low 
ventilatory drive as assessed by chemosensitivity during sleep results in lesser activity of
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the upper airway dilator muscles as compared to the diaphragm and this again 
predisposes to upper airway collapsibility.
UPPER AIRWAY:
Nasal and pharyngeal resistances increase during sleep (31,32). The narrowing of the 
pharyngeal lumen may be restricted to few segments such as at the level of the palate or 
in the portion of the pharynx posterior to the tongue. The upper aiiway collapsibility 
seen in obstructive sleep apnoea is also confined to these sites (33). The upper airway 
during sleep is thought to behave like a Starling resistor (34). High upper aiiway 
resistance or increased driving pressure across the segments (either due to high pressure 
applied to highly compliant aiiw^ay or the pressure difference generated due to the 
hypotonic pharyngeal muscles) predisposes the upper airway to collapse.
LOWER AIRWAY:
During sleep there is reduced alveolar ventilation due to fall in the central respiratory 
drive, reduction in respiratory motor output, increased upper airway resistance due to 
hypotonia of the pharyngeal muscles and blunted protective reflexes. Laryngeal and lung 
resistance do not change in sleep. Lung volumes decrease only slightly in healthy non- 
obese individuals but the changes will be greater in the obese. As a result of all these 
factors, nocturnal PaCOz rises mildly even in normal people (35-37).
During NREM sleep, there is reduced ventilation and in fact there is evidence of 
increased work of breathing in the form of increased activity of intercostals and the
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diaphragm which maintains the lung volumes only slightly less to that of the upright 
posture (38).
The REM sleep as first described by Aserinsky and Kleitman in 1953 (39) stresses the 
respiratory system in interesting ways. REM sleep comprises of phasic REM associated 
with bursts of rapid eye movement and tonic REM, between the bursts. The distinction is 
better appreciated in animal studies than in humans where the eye movement densities 
tend to be widespread during REM sleep. The tidal volume is aimed to be maintained as 
in NREM sleep but with greater excursions of the diaphragm activity and marked 
suppression of the chest wall muscles. However the relative hypercapnia and failure to 
compensate the resistive loads could well result in reduced tidal volume (40). Breathing 
tends to be more irregular, shallow and rapid especially during phasic REM. The 
breathing pattern during REM sleep is summarised in fig 1.2.1 (41).
In conclusion, sleep tests the efficiency of the respiratory system and the ventilatory 
indices.
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Fig 1.2.1: This experiment in 10 normal men showed that during eye movements (EMs), 
there was significant increase in the breathing frequency predominantly due to reduction 
in expiratory time; Tidal volume and minute ventilation fell in comparison to periods of 
sleep without eye movements (Adopted with Permission from - Gould G A, Gugger M, 
Molloy J et al. Breathing pattern and eye movement density during REM sleep in 
humans. Am Rev Respir Dis 1988;138:874-877).
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1.3 RESPIRATORY MUSCLES IN HEALTH
It was believed for a long time that the diaphragm is the only muscle of breathing. Galen 
identified that intercostal and other accessory muscles played an important role in 
breathing (42). Though Leonardo da Vinci made the analogy between breathing and a 
pair of bellows, it was only in early 1900s that John Mayow described the mechanics of 
breathing in a greater detail (43). Hutchinson quantified the respiratory muscle strength 
for the first time (44).
Stmcturally and functionally respiratory muscles are skeletal muscles and their function 
is to displace the chest wall rhythmically to pump air in and out of the lungs. Just like the 
other muscles, they are composed of fibres, a number of which will be imiervated by a 
single motor neurone to form a motor unit. The fibres merge with the connective tissues 
distally and each is surrounded by a membrane system, which also extends between the 
bundles of myofibrils that comprise a muscle fibre. In turn, eaeh myofibril consists of 
bundles of interdigitating thick and thin filaments of aetin and myosin. These protein 
molecules form the basis of the contractile apparatus within the muscles. Acetylcholine 
released from the motor end plate of the motor neurone leads to depolarization of the 
muscle cell membrane causing release of calcium. The caleimn uptake by the protein 
molecule, troponin, leads to cross bridge formation between actin and myosin molecules 
and the relative movement of the two molecules causes shortening of the myofibril. The 
process of cross bridge formation and release is driven by conversion of adenosine 
triphosphate to diphosphate.
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The force generated within the skeletal muscles is related to the length of the muscle at 
the time of stimulation (force-length relationship), the speed of muscle contraction (force- 
velocity relationship), the frequency of stimulation (force-frequency relation) and the 
integrity of the contractile apparatus.
Force-length relationship:
The optimal length for maximal force generation is the resting length of the muscle (45). 
As lung volume increases toward TLC the force generating capacity is reduced.
Force-velocity relationship:
The more rapidly a muscle shortens, less is the tension that can be achieved (46). The 
velocity of shortening is best estimated in physiological studies by measuring the rate of 
airflow and it is the speed of muscle contraction that determines the maximal airflow in 
normal subjects (47). It is also possible to assess the velocity of shortening by measuring 
the rate of contraction of the muscles, which can be estimated by quantifying the time to 
peak pressure (48).
Force-frequency relationship:
The muscle contraction elicited by a single stimulus is a twitch (Tw). The force generated 
by a muscle increases as the frequency of stimulation increases until a tetanic contraction 
is induced at high levels of stimulation (49). The repetitive stimulations allow little time 
for relaxation of the muscle between contractions and this results in a summation of the 
contractions and a resultant increase in force development (50). The tetanic plateau of the
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force-frequency curve occurs in the respiratory muscles between 50 and lOOHz (51,52). 
For maximal foree generation in respiratory muscles a stimulation frequency of 
approximately lOOHz is required.
The upper aiiway museles, diaphragm, chest wall muscles and abdominal wall muscles 
are individually dealt with in my thesis bearing in mind that they normally work together 
in a coordinated manner. The interrelationship between the thoracoabdominal 
movements and the respiratory muscle contraction is posture dependent. For instance, in 
upright posture due to gravity, abdomen is distended and abdominal muscles are 
lengthened. On assuming a supine posture there is reduction in anteroposterior diameter 
with variable change in lateral diameter (53). Therefore the length of the abdominal 
muscles decreases. Cephalad diaphragmatic movement in supine posture increases the 
A-P and lateral diameter of the rib cage and thoracic expiratory muscles are put at an 
advantage.
UPPER AIRWAY MUSCLES:
The upper airway is a complex conglomeration of bones, muscle bundles and mucosal 
structures in a narrow space (fig 1.3.1). Though upper airway muscles are not strictly 
called ‘respiratory muscles’ their pre activation prior to diaphragm contraction is required 
to stabilise the upper airway. Loss of pre activation of these muscles is important in the 
pathogenesis of obstructive sleep apnoea hypopnoea syndrome (54). As upper airway 
collapsibility is commoner in patients with neuromuscular diseases, I have discussed 
important functions of upper aiiway muscles here. The muscles comprise those of 
external nares, oral cavity, soft palate, pharynx and larynx. Though phasic activity of
2 0
genioglossus muscle can be recorded during wakeful state, it is masked by the 
pronounced tonie aetivity. Tonieity is reduced during sleep and phasic activity becomes 
easier to pick up. Phasic inspiratory activity during quiet breathing can also be 
demonstrated in alae nasi, tensor veli palatini and the vocal cord abductors.
T ongue
H ard Palate 
oft Palate
harynx
Larynx
Fig 1.3.1; Upper airway: Adopted and modified from ‘Snoring and Sleep Apnoea 
Syndrome’: Hilton M F.
DIAPHRAGM;
Diaphi'agm is a thin musculotendinous structure in which muscle fibres radiate from a 
central tendon. It is the main inspiratory muscle and accounts for 70% of inspiratory 
effort during tidal breathing (55). The crural (or vertebral) portion arises from the 
ventrolateral aspect of the first three lumbar vertebrae and the aponeurosis of arcuate 
ligaments. The costal portion inserts on the xiphoid process of the sternum and the upper 
margins of the lower six ribs. The costal fibres are closely apposed to the inner aspect of 
the lower rib cage forming the ‘zone of apposition’. Phrenic nerves originating from the 
third, fourth and fifth cervical segments form the motor supply of the muscle. The
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anterior or sternal part of the diaphi'agm is preferentially innervated by axons from 
motoneurones in the cranial end of the phrenic motor column; lateral or costal fibres, by 
axons from the middle of the column and the cmral fibres from the caudal end of the 
column. The internal mammary, intercostals and phrenic arteries supply the diaphragm 
with extensive anastomoses within the arterial network. Most of the venous drainage is 
tlirough the inferior phi*enic vein, which drains into the inferior vena cava. Though the 
heart muscle receives more blood supply than that of the diaphragm both during rest and 
exercise, the percent increase in blood flow to the diaphragm is higher in comparison to 
other organs during exercise (56).
Action:
Diaphragm contraction results in outward displacement of the anterior abdominal wall, 
caudal movement of the upper ribs and expansion of the lower rib cage circumference. 
The reduction in cross sectional area of the upper rib cage is due to the effect of negative 
pleural pressure as it has been shown to be abolished by introduction of bilateral 
pneumothoraces in animal experiments followed by diaphragm contraction (57). Hence 
diaphr agm has inspiratory action on the lower rib cage and expiratory action on the upper 
rib cage. The expansion of the thoracic cavity in the craniocaudal axis reduces the pleural 
pressure and depending on whether the airways are open or elosed, lung volume increases 
or alveolar pressure falls. The inspiratory action also depends on the lung volume. 
Towards TLC, the zone of apposition disappears, diaplnagm muscle fibres lay 
transversely and this effect makes the diaplnagm expiratory. Inspiratory activity of the 
diaphragm results in part from the force the muscle applies due to its insertions [referred
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to as the ‘insertionaî forces’] (58) and also to ‘appositional forces’ (59, fig 1.3.2). During 
breathing, the change in pressure in the pleural recess between the apposed diaphi'agm 
and the rib cage is almost equal to the change in abdominal pressure, i.e., pressure in the 
pleural recess rises supporting the view that the rise in abdominal pressure gets 
transmitted thiough the apposed diaphi'agm to expand the lower rib cage.
Zone of 
apposition |
Fig. 1.3.2: When the abdominal resistance (open aiTow) is high, zone of apposition 
remains significant throughout inspiration and there is considerable expansion of the 
lower rib cage. If the abdominal resistance is low (right panel), diaphragm descends 
more, zone of apposition is reduced and the inspiratory activity of the diaplnagm on 
lower rib cage is less pronounced. (Reproduced with permission from Respiratory muscle 
function - André de Troyer in Respiratory Medicine ed., Brewis, Corrin, Geddes, Gibson 
- Saunders 1995).
Based on the myosin heavy chain isoform skeletal muscle fibres are classified as slow 1 
(fatigue resistant), fast 2A (intermediate fatigue resistance), fast 2X and fast 2B (easily 
fatiguable). Type 2B is not expressed in human muscle (60). The muscle fibres 
comprising the diaphi'agm show predominance of fatigue resistant type. About 50% are 
slow fibres, which have high oxidative and low glycolytic capacity and bear small fibre 
size with numerous capillaries. The high aerobic capacity of these fibres makes them 
fatigue resistant. About 20% fibres are type 2A that have high oxidative and glycolytic
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capacities. The remaining 30% are type 2X fibres, which have low oxidative and high 
glycolytic activity and are susceptible to fatigue (61). The intercostal muscles also show 
a high proportion of slow fibres. However the slow/fast nature of these fibres is not fixed 
and can be modified by training, hypoxia, age, disease states and pharmacological agents 
(62,63). For instance in rabbit diaphragm it has been shown that during tachypnoea, 
there is shift in recruitment from slow to fast muscle fibres (64,65). Drugs such as 
steroids and beta agonists can alter the density and types of fibres. Chonic use of beta 
agonists has shown to result in hypertrophy of fast fibres and switch from slow to fast 
fibre types. In murine models of muscular dystrophy shift from fast to slow fibre types is 
evident (1 and 2A fibres).
RIB CAGE MUSCLES;
The chest wall consists of the ribcage and the abdomen separated by the diapliragm. The 
movement of the ribs in humans is shown in fig 1.3.3. The external intercostal muscles 
extend from the tubercles of the ribs dorsally to the costochondral junctions ventrally, 
with their fibres orientated obliquely caudal and ventral from the rib above to the rib 
below.
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Fig 1.3.3: Movement of the ribs in man: The ribs rotate around the axis of the neck 
(heavy broken line) and rotation increases anteroposterior and transverse diameters of the 
rib cage (dotted line). (Reproduced with permission from Respiratory muscle function - 
André de Troyer in Respiratory medicine ed., Brewis, Coii'in, Geddes, Gibson - Saunders 
1995).
The internal intercostal muscles on the other hand extend from the angles of the ribs 
dorsally to the sternocostal junctions ventrally with the fibres running obliquely caudal 
and dorsal from the rib above to rib below. The fibres are particularly thick between the 
sternum and the chondrocostal junctions and they are called as ‘parasternal 
intercostals’. The parasternal intercostals act directly on the rib cage expanding it in 
anteroposterior and lateral diameters. Along with the diaphragm they form the primary 
muscles of inspiration. Nei*ve supply to all the intercostal muscles is tlirough the 
intercostal neiwes. External and parasternal intercostals are most active during inspiration 
and the internal intercostals during expiration. The contribution of external and internal 
intercostals to tidal breathing is small.
Scalene muscles are in three bundles mmiing from the transverse processes of the lower 
five ceiwical vertebrae to the upper surface of the first two ribs. Scalene muscles are
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innervated by the lower five cervical segments. Though traditionally classified as the 
accessory muscles of respiration, scalene muscles contract in normal humans with the 
diaphragm and the parasternal intercostals during inspiration (66). Contraction of the 
scalene muscles results in expansion of the upper rib cage.
OTHER ACCESSORY MUSCLES OF RESPIRATION:
Sternocleidomastoid, pectoralis minor, trapezius, erector spinae, serrati have 
predominantly postural frinctions but assist inspiration during increased requirements. 
The clavicular portion of the pectoralis major assists expiration when the requirement is 
high as in paralysis of the abdominal muscles due to spinal cord injury.
Triangularis sterni (Trans vers us thoracis) is a flat muscle deep to the sternum and 
parasternal intercostals supplied by the intercostal nerves. Though inactive during resting 
breathing, it contracts during voluntary or involuntary expiratory efforts such as laughing, 
coughing and speech.
ABDOMINAL MUSCLES:
Muscles within the anterior abdominal wall are the chief expiratory muscles, Trans versus 
abdominis, internal oblique, external oblique and rectus abdominis have important 
respiratory function apart from their work as rotators and flexors of the trunk. On 
contraction, they pull the abdominal wall inwards increasing the abdominal pressure and 
move the diaphragm cranially reducing the lung volume. Secondly, they pull the lower 
ribs caudally deflating the rib cage thereby aiding expiration. They also have an
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inspiratory effect by equalising the pressure in the pleural recess to that in the abdomen 
thereby raising the lower rib cage as discussed above. At end expiration they relax, 
causing passive descent of the diaphragm aiding inspiration. It has been shown that in 
healthy subjects, phasic expiratory contraction occurs when the demand on the 
inspiratory muscles increases as in exercise (67). The tonic contractions of these muscles 
in standing posture makes the diaplnagm longer at the onset of inspiration and prevents 
over-shortening during expiration. In accordance with the length-tension characteristics 
of the muscle, diaphr agm capacity to generate pressure is thus entranced.
In conclusion, pharyngeal dilators, diaphragm and the rib cage muscles work in a 
coordinated fashion to aid tidal breathing. Accessory muscles of respiration contribute 
during periods of increased demand such as exercise.
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1.4 RESPIRATORY MUSCLE STRENGTH ASSESSMENT
The recent developments with regard to measuring pulmonary mechanics have focussed 
on patients with rmexplained breathlessness, neuromuscular diseases and patients who are 
difficult to wean from ventilators. Measurement of respiratory muscle strength forms an 
important part of assessment in these groups of patients.
Symptoms of Respiratory Muscle Weakness:
Mild to moderate respiratory muscle weakness can be asymptomatic unless there is an 
additional load on the respiratory system such as superadded infection, airflow 
obstruction or pulmonary fibrosis. Most common symptom is breathlessness on exertion 
(68,69). Associated limb muscle weakness may mask this disabling symptom (70). As the 
disease progresses, dyspnoea may occur at rest signifying imminent respiratory failure. 
With marked respiratory muscle weakness, nocturnal hypoventilation ensues with sleep 
fragmentation resulting in unrefieshed sleep, excessive daytime sleepiness, tiredness, 
poor concentration and memory. Hypercapnia causes cerebral vasodilatation that could 
result in throbbing, especially morning headaches when PaC0 2  may be greatest.
Unilateral diaphragm weakness is usually asymptomatic. However patients with severe 
unilateral diaphragm weakness can develop ventilatory problems following an 
anaesthetic or experience dyspnoea with supine posmre, bending or iimnersion in water 
(71). With bilateral diaphragm paralysis subjects are likely to experience orthopnoea or 
dyspnoea on exertion.
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Weakness of expiratory or bulbar muscles results in difficult speech, failure to clear 
secretions or aspiration culminating in recurrent lower respiratory tract infections (72).
Signs of Respiratory Muscle Weakness:
Physical examination may reveal signs that suggest the underlying aetiology for the 
respiratory muscle weakness. There may be gross wasting of the muscles, which is better 
appreciated in the neck accessory muscles than the intercostals. Associated myotonia, 
fasciculations, absent or exaggerated deep tendon reflexes, sensory disturbances could 
also help in localising the level of lesion within the nervous system.
During initial stages of the disease examination may be normal. With progression of 
respiratory muscle weakness, tachypnoea at rest manifests with reduced tidal volume. 
This rapid shallow breathing is an adaptation to lower the elastic work of breathing but 
increases the dead space ventilation. This is thought to be a response to the imbalance 
between the strength and the load on the respiratory system (73,74).
Diaphragm Paralysis:
Selective diaplnagm weakness results in compensatory increase in the activation of 
inspiratory rib cage muscles. The fall in pleural pressure gets transmitted across the 
flaccid diaphragm so that the abdominal pressure falls and there is paradoxical inward 
movement of the abdomen with inspiration, opposing the lung inflation (71). This is 
usually better appreciated in supine posture, more pronounced when the weakness is 
severe (maximal transdiaphiagmatic pressure < 30 cm H2O) and occurs when there is still
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adequate extradiaphragmatic upper chest wall muscle strength. If the ribcage muscles 
are predominantly involved there may be paradoxical thoracic inward movement during 
inspiration (75). Rarely both the patterns may be apparent in the same individual at 
different times and this has been termed ‘respiratory alternans’. It is postulated that this 
may be a central mechanism to avert fatigue in different groups of muscles.
Laboratory Assessment;
Normally comparing the motor neiwe input of the muscle to the force and movement 
developed within it assesses its function. Since the length-tension relationship of the 
respiratory muscles alter with different body postures, the usual methods to assess 
strength in limb muscles can not be routinely applied to the respiratory muscles.
ELECTRICAL ACTIVITY; Needle electromyography can be performed for accessory 
muscles of respiration such as the sternocleidomastoid and scalene s. Oesophageal 
electrode has been used successfully to assess diaphragmatic activity. Since diaphragm, 
intercostals and abdominal muscle lie close to pleural and peritoneal cavities, surface 
electrodes are the preferred choice to measure electrical activity routinely in these 
muscles. Anterolateral chest wall is commonly used to measure diaphragm surface 
EMG, as there are relatively few external intercostal fibres in the region. However the 
signals are affected by the activity of internal intercostals and possibly abdominal 
muscles. Use of oesophageal electrodes avoids this interference. EMG signals can be 
integrated to provide quantitative estimate of contraction. Spectral analysis on the other 
hand is a useful non-invasive measure of muscle fatigue.
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MECHANICAL ACTIVITY: Since respiratory muscle contraction results in force 
generation, the subsequent pressure changes measured in vivo provide quantification of 
their strength (76). Transpulmonary, transthoracic, transabdominal and 
transdiaphragmatic pressure measurements, all provide useful information regarding the 
respiratory muscle activity.
Full Lung Function Tests:
Commonly measured lung volumes in the respiratory laboratories are depicted in fig 
1.4.1.
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Fig 1.4.1: Shows different lung volumes.
Monitoring vital capacity (VC) is simple and useful for repeated measurements as in 
impending respiratory failure due to Guillain-Barre syndrome. Supine vital capacity falls 
less than 10% (mean 7.5%, SD ± 5.7%) of that due to sitting values in normal people 
(77). Again this is due to the loss of gravity assistance to diaphragm descent but this has 
no functional consequence. A greater than 25% fall in supine vital capacity suggests
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significant diaphragm weakness. However it is a volitional test and a non-specific marker of 
respiratory muscle weakness. Also VC can be completely normal in mild to moderate weakness. 
In later stages of respiratory muscle dysfunction, F VC has been shown to be a better 
predictor of morbidity (78).
Some studies have shown increased FEVi and mid expiratory flow rates (79, 80) and this 
is generally attributed to patent airways at lower driving pressure maintaining higher flow 
rates. TLC and FRC tend to he reduced when there is significant weakness. Residual volume 
(RV), if high, suggests significant expiratory muscle weakness. Diffusion analysis usually yields 
low carhon monoxide diffusion capacity (TLCO) with normal or raised transfer coefficient 
(KCO) suggesting normal diffusion within the alveoli available for gas exchange, in keeping with 
extrathoracic restrictive defect. Though conventional methods are used to measure lung 
volumes, computed tomography to reconstruct three-dimensional images of thorax or 
magnetic resonance imaging can also be used.
Flow volume loops:
Sometimes even when the vital capacity is within the normal range the appearance of the 
flow volume loop can indicate underlying respiratory muscle weakness (fig 1.4.2). 
Characteristically it shows delayed peak of the expiratory limb, abrupt drop of the forced 
expiratory flow near the residual volume, blunting of the inspiratory and expiratory limbs 
(81). In distinction to normal forced expiratory flow volume cuiwe, the peak flow as well 
as the terminal segment after FRC is effort-dependent. Upper airway dysfunction can 
also become apparent on flow volume loops. Flow oscillations are commonly seen in 
patients with clinically evident bulbar dysfunction. If incorrect scaling is used, observer 
can misinterpret the data to represent upper airway obstruction. Most labs use the ATS
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standard of plotting 2L/s flow against IL of volume to avoid this error (82). Flow 
volume loops however are not useful to compare variations between individuals and have 
not been tested in population screening for neuromuscular diseases.
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Fig 1.4.2: Flow volume loop showing respiratory muscle weakness
M odified  and reproduced with perm ission from  Harcoui t Publishers Limited; Lung function tests: P h ysio logical principles and 
clin ical applications, 1999; Eds H ughes J M B , Pride N  B,
Mouth Pressures:
Static inspiratory and expiratory pressures are commonly measured using mouth 
pressure meters. They give an assessment of the global respiratory muscle strength. The 
pressures generated tend to be higher with a tube mouthpiece in normal people compared 
to flanged mouthpiece but the perioral leaks are likely to be higher using a tube 
mouthpiece (83). The values though wide are well established (84-86) and tend to be 
higher in males compared to females. The values decline with age. As with any 
volitional test, obtained values are dependent on subject motivation and effort, which 
partly explains the wide range of reported normal range. A low value can be difficult to
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interpret as this could either be due to poor effort or true muscle weakness. On the other 
hand noiinal values can be difficult to differentiate from mild respiratory muscle 
weakness. The pressures generated depend on the lung volume at which the test is 
performed. Maximal inspiratory pressure is usually measured from FRC or RV and the 
maximal expiratory pressure from TLC. Some people do find the forceful manoeuvres 
difficult and sniff tests will be useful in that instance. If maximal inspiratory pressure 
(MIP) is reduced, sniff nasal inspiratory pressure (SNIP) measured from FRC will be 
useful to detect any significant respiratory muscle weakness. A value of SNIP over 70 
cmH20 usually excludes significant respiratory muscle weakness. The basis for a SNIP 
test is that the pressure within the alveoli closely relates to the nasal pressure when the 
airway is occluded. Hence it becomes unreliable in presence of nasal anatomical 
abnormalities or pulmonary fibrosis where the pleural pressure transmission is not 
uniform. Ideally SNIP should be less than MIP considering the force-velocity and force- 
length aspects of skeletal muscles. However SNIP is often greater than MIP because (i) 
many subjects find sniffing to be an easier manoeuvre and hence muscle recruitment is 
likely to be better, (ii) Diaphragm EMG activity is higher during sniff than MIP. (iii) 
Diaphragm length appears to be more favourable to generate pressure during initiation of 
a sniff than a maximal inspiratory manoeuvre. It is generally recommended that SNIP 
and MIP be used as complementary tests in the assessments of inspiratory muscle 
strength.
If oesophageal and gastric balloon catheters are inserted, sniff oesophageal pressure 
(sniff Poes) will become a useful indicator of inspiratory muscle strength with values >
34
70 “ 80 cm H2O being normal. It has the added advantage that it is not altered by 
imperfect pressure transmission within the respiratory system as in chronic obstructive 
lung disease. It has higher maximal pressures compared to SNIP, narrower range of 
normal values and better reproducibility (87). Transdiaphragmatic pressures (Pdi) can 
also be measured if specific diaphragm assessment is required. Sniff Pdi >100 cm H2O 
signifies good diaplrragm strength. If sniff Pdi is reduced or subjects are unable to 
perform voluntary manoeuvre phrenic nerve can be stimulated electrically or 
magnetically to obtain twitch Pdi. An unpotentiated unilateral Tw Pdi > 10cm H2O and 
bilateral Tw Pdi > 20cm H2O generally excludes significant diaphragm weakness.
Cough gastric pressure (Cough Pgas) provides another useful measure of expiratory
muscle strength. It is more reproducible than MEP and normal values have recently been
reported -  214.4(42.2) for normal males and 165.1(34.8) cm H2O for females (88).
(Normal values have been adopted from Respiratory Muscles - J Moxham in Hughes and 
Pride eds. Lung function tests: Physiological principles and clinical applications 1999).
Imaging: 
Chest X Ray:
Unilateral or bilateral elevated diapluagms may be apparent due to weakened diaphragm. 
Lung volumes may appear smaller but this will be difficult to differentiate from poor 
inspiratory effort. Sensitivity is high in that the condition is unlikely if diaphragm 
weakness is absent. However the specificity of chest X ray to diagnose unilateral 
hemidiaphragm paralysis is only in the range of 0.44 (89).
35
Fluoroscopy:
Fluoroscopic examination during an inspiratory manoeuvre such as submaximal sniff in 
an upright position from FRC will be useful in some patients. False positive results are 
significant with this. Alexander et al (90) showed that 6% of normal subjects have the 
inspiratory cranial hemidiaphragm motion usually considered diagnostic of 
hemidiaphragm paralysis because of abdominal muscle relaxation.
Ultrasound:
Ultrasound examination is radiation free and can reveal the paradoxical upward 
movement of the paralysed diaphragm during inspiration but again this may only be 
appreciated in the supine posture. In upright posture this can be compensated by 
assistance of gravity. Another useful measure will be the thickness and the degree of 
shortening during inspiration as a chronically paralysed diaphragm has an atrophic 
appearance and does not thicken during inspiration (91).
In summary, significant respiratory muscle weakness can exist with minimal symptoms 
and signs. Therefore high degree of clinical suspicion along with appropriate tests will be 
required to detect the problem early.
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1.5 RESPIRATORY MUSCLES IN NEUROMUSCULAR DISEASES
It appears logical to think that any progressive neuromuscular disease eventually affects 
the respiratory muscles if not already so at the outset. Respiratory muscle weakness 
contributes to significant morbidity and mortality in patients with neuromuscular 
diseases. Respiratory muscle weakness and/or fatigue is responsible for dyspnoea, 
reduced exercise tolerance, nocturnal oxygen de saturation and prolonged weaning from 
mechanical ventilation associated with NMD. This is not a universal manifestation as 
mitochondrial myopathy (92) can present with marked diaphragm fatigability with 
relatively well-preserved mouth pressures. Ventilatory failure in this instance is because 
of the inability to sustain respiratory efforts and it has been showed that exercise 
limitation occurs sooner in comparison to normal controls (93). Inspiratory muscle 
weakness results in progressive decline in vital capacity, restrictive lung defect and 
eventually hypercapnie respiratory failure. Expiratory muscle weakness results in 
retention of secretions, impaired cough and thereby recurrent respiratory tract infections, 
which eventually contribute to reduction in vital capacity. If bulbar involvement coexists 
as in MND, aspiration episodes tend to be more frequent. In presence of underlying lung 
disease symptoms manifest early. Reduced drive is exaggerated in neuromuscular 
diseases with associated blunting of arousal threshold and reduced respiratory muscle 
activity (94). The disproportionate loss of upper airway muscle tone poses additional 
load especially during REM sleep when there is maximal muscle hypotonia (95,96) 
resulting in recurrent upper airway collapses and sleep fragmentation.
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Sleep disordered breathing manifests as nocturnal oxygen desaturations, hypopnoeas, 
obstmctive, central apnoeas and hypercapnia that occurs initially during REM sleep (97). 
Though sleep disordered breathing can develop early in the course of the disease it is not 
always apparent from daytime clinical assessment. However the pattern and severity of 
the sleep related breathing disorder could sometimes be inferred from daytime lung and 
respiratory muscle function tests (98).
It has been shown that even during episodes of upper respiratory tract infection, VC, MIP 
and MEP reduce significantly in NMD and transient hypercapnia is evident in few 
patients (99). This does not occur in normal people and highlights the delicate balance of 
the respiratory muscles in NMD. Duration of NMD and nutritional state of the patient 
has not been shown to predict the respiratory muscle weakness (100). Though there is no 
correlation between the respiratory muscle strength and the peripheral muscle weakness, 
the distribution of weakness and the type of NMD can determine the way in which 
respiratory muscles are compromised.
Since diaphragm is the main inspiratory muscle, its weakness in NMD warrants special 
mention. With unilateral diaphragm paralysis, VC has been shown to be reduced by 20- 
25% even in the upright posture and PaOz may fall in the supine posture mostly due to 
increase in the closing volume and compression of the basal segments of the lung on the 
affected side (101,102). With bilateral diaphragmatic paralysis, there is increased 
respiratory rate with reduced tidal volume at rest and alveolar hypoventilation during 
sleep (103). Ventilation perfusion mismatch occurs in the decubitus posture (104), which
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contributes to arterial hypoxaemia. Unusual phasic activity during REM has been shown 
to occur in patients with motor neurone disease (MND) with severe diaphragm weakness 
and this may well be an adaptive mechanism of the respiratory pump (105).
To conclude, in neuromuscular diseases, respiratory muscles function at a lower capacity 
and the altered peripheral mechanics with or without depressed respiratory drive 
increases the load on them. Some of the changes noted such as tachypnoea and accessory 
muscle recruitment may well be adaptive mechanisms to combat the increased load but in 
most instances respiratory failure ensues with daytime hypercapnia, although the 
timescale is variable in different conditions.
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1.6 VENTILATORY FAILURE IN NMD
Though neuromuscular diseases form a heterogeneous group of diseases, ventilatory 
failure (defined as PaOi < 8 kPa and PaCOz > 6 kPa) commonly occurs in many patients. 
It often occurs as a terminal event. Ventilatory failure can occur even in the absence of 
underlying pulmonary pathology. Associated respiratory muscle weakness and sleep 
disordered breathing tend to be important contributors to the onset of respiratory 
insufficiency. Respiratory muscle weakness may be apparent at the time of initial 
diagnosis though this is not universal. In proximal myopathy, it has been shown that 
hypercapnia is common when respiratory muscle strength is <30% predicted and VC 
<55% predicted (106).
In NMD, problems with ventilation can arise from involvement of the brain, brainstem 
nuclei, spinal motoneurones, defective neuromuscular transmission or reduced respiratory 
muscle force generation. Neuronal abnormality within the brain could either be due to 
anatomical lesion or abnoimal metabolic responses to common ventilatory stimuli. 
Normal response to hypoxia and hypercapnia includes increase in tidal volume (VT) with 
little change in the respiratory rate (f). In NMD, resting breathing pattern can often be 
abnormal and there may be low VT and high f  response to hypoxic or hypercapnie 
stimuli. Though defective central control could result in this, often the peripheral 
mechanics due to respiratory muscle weakness will account for this. The specific 
problem of assessing drive in presence of weak muscles is discussed in section 1.8.1.
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Table 1,6.1: Classification of NMD that compromise ventilation depending on the 
primary level affected.
Muscles Neuromuscular
Junction
Neurogenic Others
Dystrophies Myasthenia gravis MND/ALS Drugs
Myopathies Tetanus Poliomyelitis Metabolic
Connective tissue disease Snake Bite Guillain Barré Syndrome
(SEE, polymyositis) Botulism Phrenic nerve palsy
COPD Sepsis (surgery, trauma, carcinoma)
Chronic heart failure Stroke
Kyphoscoliosis Parkinson's Disease 
Multiple sclerosis 
Spinal cord injury
Nocturnal hypoventilation especially during REM sleep is a recognised initial 
manifestation. By the time patients are symptomatic, when non-invasive ventilation is 
introduced, ventilatory failure tends to be established with daytime hypercapnia. The 
recognition of symptoms such as breathlessness may be delayed, as exercise tends to be 
limited due to associated muscular weakness. Hence high clinical suspicion with 
supportive laboratory assessments will be needed to identify patients at risk of developing 
ventilatory failure. This is increasingly important as evidence shows the benefit of non- 
invasive ventilation in these conditions by prolonging survival, improving quality of life 
and blood gas parameters.
With mild to moderate respiratory muscle weakness, ventilatory drive is increased and 
results in hyperventilation. Hence in early stages arterial blood gas analysis will reveal 
normal pH and reduced PaCOi. However PaOi and alveolar-arterial (A-a) gradient 
remains normal unless there is compromise within the lung parenchyma. With 
progression, nocturnal rise in PaCOg and eventually daytime hypercapnia ensues (107).
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In essence, there is a combination of reduced drive, increased load and decreased 
capacity ’which initially manifests as hypoventilation during REM sleep and in later 
stages with daytime hypercapnia and progression of symptoms. The contribution of these 
three factors in the pathogenesis of ventilatory failure can be different depending on the 
underlying aetiology. For instance respiratory drive tends to be well preserved in 
Duchemie muscular dystrophy but impaired in many patients with myotonic dystrophy. 
The extent and progression of respiratory insufficiency is also variable depending on the 
underlying NMD. NIV at present is being offered depending on the local availability, 
expertise and financial assistance provided for such services. NIV is likely utilised better 
if respiratory muscle strength assessments are carried out at regular intervals as patients 
have time to develop an understanding of the progression of the disease and proposed 
inteiwentions. At present symptoms and arterial blood gas parameters remain pivotal in 
evaluation of these patients to plan appropriate management.
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1.7 SHOULD RESPIRATORY MUSCLE STRENGTH BE ASSESSED IN NMD?
It can be argued that vital capacity in conjunction with arterial blood gas analysis alone 
provides enough clinical information that would assist in planning the required medical 
intervention. That poses the question: Is it really necessary to measure respiratory
muscle strength in NMD? In established ventilatory failure, VC and blood gases may 
well be sufficient to plan further management. However, with the advent of the newer 
genetic modalities/screening many NMD patients are being diagnosed in 
early/asymptomatic stages of the disease. At the same time research has started to 
umavel the frequency with which respiratory problems occur in these patients in greater 
detail. The involvement of inspiratory and expiratory muscles can differ between the 
diseases and mode of intervention will also be different. There is increasing awareness 
amongst both patients and medical professionals regarding the benefits of inspiratory 
muscle assists in the form of non-invasive ventilators and expiratory aids such as 
insufflator -  exsufflator devices (108). Although myopathy can result mostly from 
fatigability in the presence of normal mouth pressures as in mitochondrial myopathy, 
commonly neuromuscular diseases tend to present with low mouth pressures. VC can be 
entirely normal in mild to moderate respiratory muscle weakness and awake blood gases 
are usually normal in earlier stages of the disease. Hence it would be essential to have 
formal assessment of respiratory muscle strength to provide better care for NMD patients. 
I will now describe the background work on the respiratory assessment in Myotonic 
dystrophy and Motor neurone disease (the two main conditions I studied).
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1.8 REVIEW OF LITERATURE ON MyD AND MND
1.8.1 Respiration in MyD -  What we already know:
MyD is the commonest adult muscular dystrophy that exhibits the phenomenon of 
genetic anticipation occurring at younger age and in more severe form with successive 
generations. It affects 1 in 8000 persons worldwide. There are over 750 patients within 
Scotland. At present in the West of Scotland with around 280 patients, it is estimated that 
one to two affected family members are missed with the existing screening programme 
(personal communication, Dr Wilcox, Scottish Muscle Network, 2004). There is 
emerging evidence of the benefit with NIV in respiratory failure due to myotonic 
dystrophy in terms of symptoms and blood gas parameters. However the NIV 
compliance has been shown to be lower than in a group of age and sex matched post 
poliomyelitis patients requiring NIV (109).
Myotonic dystrophy type I results from unstable expansion of the trinucleotide (CTG) 
repeats on the long arm of chromosome 19 (19ql3.3). The size of the trinucleotide 
repeats in the normal population varies from 3-30. Greater than 40 CTG repeats is 
associated with myotonic dystrophy (110). All the patients I studied belonged to type I 
myotonic dystrophy (MyD) group. MyD usually presents during second or third decade 
of life with myotonia, generalised progressive muscle weakness, characteristic facial 
appearance of ptosis and frontal balding, cataracts, diabetes mellitus, gonadal atrophy and 
neuropsychiatrie disturbances (111). The median survival at present extends only to fifth 
- sixth decade of life. The main causes of death include cardiac conduction defects and
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respiratory complications. Approximately half the deaths are related to respiratory 
complications in the form of pneumonia or respiratory failure. Generally four disease 
types have been recognised - late onset (mild), adult onset (classical), childhood and 
congenital (112). The implications I have discussed mostly concentrate on the classical 
variety of the disease.
Respiratory Muscle  ^Cential Resphatory
Weakness _ Drive
Pulmonary hypoplasia -   —> Failure ^ ---------- Aspiration
Congenital Myotonic 
Dystrophy
Myotonia Upper Airway
Collapsibility
Fig 1.8.1.1: Schematic presentation of factors that affect ventilation in Myotonic 
Dystrophy
The complex interaction between the various parameters is yet to be completely 
understood and may vary between individuals of the same family. As in other 
neuromuscular diseases due to restricted activity symptoms of respiratory muscle 
weakness can be masked till later in the course of the illness. Sleep complaints are 
prevalent even in absence of nocturnal respiratory disturbance. It has been shown that 
patients with excessive daytime sleepiness report greater hypnagogic hallucinations and 
pain associated with nocturnal awakenings (113).
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Respiratory Drive:
As a direct measure of respiratory centre output is not clinically possible, many other 
physiological parameters are used as a surrogate of this drive. Irregular breathing pattern 
at rest during wakefulness (114,115) has been described mostly with increased 
respiratory rate and reduced tidal volume. It has been postulated that input from the chest 
wall receptors might be enhanced in presence of myotonia thereby leading to tachypnoea 
though conclusive evidence is lacking. Respiratory muscle weakness in itself and/or 
altered peripheral respiratory mechanics could account for this. In addition, abdominal 
muscle recruitment as evidenced by EMG activity tends to be higher in these patients 
during resting breathing. In association with expiratory muscle weakness this may well 
contribute to abnormal breathing pattern and increased work of breathing (116). Duty 
cycle (determined by Ti/Ttot that represents the inspiratory-phase fraction of the 
respiratory cycle. Ti = inspiratory time, Ttot = total duration of the respiratory cycle) and 
cential inspiratory drive [measured as tidal volume (VT)/Inspiratory time (Ti)] have been 
shown to be well preserved compared to normal controls.
Occlusion pressure (P o .i) is either normal or slightly higher than in control subjects at rest 
which suggests noiiual resting central drive in few patients (117). However this has to be 
interpreted with the knowledge that Po.i represents only a small fraction of the total 
muscular pressure generated for the tidal volume and is independent of the maximal 
pressure limitation reached in the latter half of inspiration. This may well explain why 
only a group of patients studied show abnormal drive. Another interpretation is that 
‘measured normal drive' in the face of respiratory muscle weakness may be
46
inappropiately low to maintain alveolar ventilation. Reduction in pulmonary compliance 
results in greater pressure generation to produce the same level of ventilation.
It has been shown in 12 patients that moderately severe global respiratory muscle 
weakness does not influence ventilatory response to hypercapnia or the perception of 
inspiratory effort [MIP 43.1(17.2) cm H2O vs 123(15.2) cm H2O in normal controls] 
(118). This is in contrast to earlier studies, which had shown depressed ventilatory 
response to chemical stimulation. It appears that patients with normal PaCOi retain 
sensitivity to CO2 stimulation (119). Since there is no direct coiTelation between CO2 
retention and the hypercapnie ventilatory response (114), it is likely that additional 
factors apart from respiratory muscle weakness per se operate. One such hypothesis 
suggests that disordered afferent infonnation from the affected muscles could impair the 
function of the respiratory centre. When there is significant respiratory muscle weakness 
and altered pulmonary mechanics, the central neural diive may not be translated into 
alveolar ventilation due to ‘neuro mechanical uncoupling' and this may well be the 
reason for reduced slope of HCVR.
Central mechanisms may play a key role in this as well. In support is the study in a small 
group of myotonic dystrophy patients where the densities of the neurones in dorsal, 
ventral central medullary nuclei and sub trigeminal medullary nucleus have been shown 
to be reduced. All these subjects had abnormal hypercapnie ventilatory response and 
central hypoventilation in comparison to normal controls and patients without
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hypoventilation (120). Another factor being the frequent occurrence of central apnoeas 
in MyD (121).
Pulmonary function tests:
Restrictive spirometry is commonly apparent in later stages of the disease. Vital capacity 
declines as the respiratory muscle weakness progresses. Total lung capacity (TLC) tends 
to be reduced. Residual volume (RV) is usually normal. If RV is high this usually 
signifies expiratory muscle weakness. Maximal voluntary ventilation (M W ) can either 
be in the normal range or reduced. When M W  is limited it usually is associated with 
hypoxaemia at rest (122).
Respiratory muscle strength:
Mouth pressures tend to be reduced. MEP tends to be more impaired than MIP. 
Associated facial muscle weakness interferes with the Valsalva and Muller manoeuvres 
and thereby underestimates the strength using these non-invasive tests. Table 1.8.1.1 
gives a summary of the mouth pressures and % predicted vital capacity in Myotonic 
Dystrophy patients available in the literature.
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It appears that the severity of respiratory muscle weakness usually does not significantly 
correlate with either the pulmonary function variables or clinical severity. Significant 
reduction in static mouth pressures can occur even when the vital capacity and the arterial 
blood gases remain within the normal range. Sniff Pdi measurements have been studied 
in MyD but to date nonvolitional diaphragm strength using BAMPS has not been 
routinely assessed in this group.
Sleep in Myotonic Dystrophy;
Respiratory failure worsens during sleep. Nocturnal desaturations and upper airway 
collapsibility are far more frequent in MyD than in other neuromuscular diseases with 
similar degree of respiratory muscle weakness (123). Sleep dismption is encountered 
even in patients without obstructive apnoeas or hypopnoeas. Reduced sleep efficiency 
(ratio of total sleep time to time in bed), reduced total sleep time, increased percentage of 
stage 1 and reduced slow wave sleep, frequent wakenings at night are commonly seen. 
Increased stage 1 sleep is not consistently reported and in the studies, which have 
reported this, the result may well be due to the ‘first night effect’ in the sleep laboratory 
(124).
Non-invasive ventilation (NIV) is an efficient tool not only to relieve symptoms of 
hypoventilation, improve blood gas parameters in neuromuscular and chest wall diseases 
(125-129) but also to improve quality of life and prolong survival in its users (130-132). 
Optimal time for introducing NIV can be difficult to identify in individual patient setting 
and often sleep studies are used for early identification of ‘patients at-risk’ as it is well
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established that nocturnal sleep abnormalities precede daytime hypercapnia. It is also 
widely known that sleep worsens the respiratory impairment in chronic neuromuscular 
diseases (97,133). The usefulness of screening sleep studies however is debatable as 
nocturnal measurements are poor predictors of survival. It has also been shown that sleep 
and nocturnal respiratory parameters correlate poorly (134).
Excessive daytime sleepiness:
Excessive daytime sleepiness, which is out of proportion to nocturnal events, is 
commonly reported in this group of patients. Multiple sleep latency test carried out in 6 
patients were normal and no sleep onset rapid eye movements (REM) have been recorded
(135) though other investigators have noted diurnal and nocturnal sleep onset REMs
(136). A central sleep control defect could account for excessive sleepiness in these 
patients.
Myotonia:
Myotonia of the respiratory muscles has been demonstrated using fluoroscopy and 
electromyogram using intramuscular electi'odes (137). Myotonia can also be observed on 
invasive respiratory muscle sti'ength assessment where slow decay of the 
transdiaplrragmatic pressure tracings is apparent during sniffs (138). Myotonia is a rare 
occurrence during tidal breathing but has been shown to occur more frequently at higher 
levels of ventilation and this may well be a contributor towards reduced ventilatory 
response to chemical stimuli. Myotonia of the respiratory muscles means that greater 
diaphragmatic pressure has to be generated for each inspiration and this may in itself
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reduce the fatigue threshold of the diaplmagm. Myotonia can induce dyspnoea in two 
ways. Firstly, by placing the inspiratory luuscles in an unfavourable length -  tension 
relationship. Secondly, an enhanced reciprocal inhibition on spinal motoneurones 
supplying intercostal muscles can result in abnormally active expiratory intercostal 
muscles with reduced activity of inspiratory muscles. Such inhibition in limb muscles is 
compensated by increased activation of supraspinal centres but the compensation in 
respiratory muscles is less well understood. There are isolated case reports in the 
literature that suggest improvement in breathlessness after antimyotonic therapy such as 
procainamide (138) though there are no long term studies in this regard. Also associated 
side effects of these drugs make longer-temi use difficult.
Aspiration:
Associated cardiac sphincter malfunction along with delayed gastric emptying (139) can 
lead to episodes of aspiration resulting in recurrent lower respiratory tract infections 
requiring antibiotics. Acute respiratory insufficiency can be precipitated post operatively 
after a general anaesthetic due to aspiration.
Anaesthesia and Myotonic Dystrophy:
It has been shown that central depressive agents such as thiopentone delivered as an 
aerosol exaggerates the abnormal breathing pattern in Myotonic dystrophy (140). Good 
preoperative assessment can help prevent many of the complications. Ideally short acting 
non-depolarising neuromuscular junction blockers (e.g. atracurium or vecuronium) 
should be used so as to avoid need for neostigmine. Opiate use should be minimised and
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sedative premedications avoided. Aspiration is a potential problem to be anticipated. 
Post operatively patients should be monitored in high dependency units with 
monitoring of oxygen saturation, avoiding sedation and constant watch out for evidence 
of infection. Chest physiotherapy should be prompt to avoid respiratory complications.
In summary, myotonic dystrophy patients have significant abnormalities on static mouth 
pressure assessments even when the muscular disability is only minimal. These patients 
fiequently have facial muscle weakness and hence low mouth pressures obtained dming 
routine testing needs to be interpreted with caution. However normal lung function tests 
and mouth pressures would be helpful in excluding significant respiratory muscle 
weakness. A combination of reduced strength, increased load and probably low central 
ventilatory drive at least in a subset of patients eventually results in chronic hypercapnia. 
Aspiration and general anaesthesia in unsuspected patients are the likely sources of acute 
respiratory insufficiency in the present day. Central stimulating drugs such as modafinil 
and its evidence-based use in myotonic dystrophy may well help to understand certain 
central features of the disease and thereby open up new therapeutic avenues alongside 
NIV.
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1.8.2 Respiration in Motor Neurone Disease -  what we know:
Amyotrophic lateral sclerosis (ALS) is the commonest type of adult-onset motor neuron 
disease (MND). ALS involves both upper and lower motor neurones and presents as an 
idiopathic, progressive degeneration of anterior horn cells and their associated neurons 
resulting in progressive muscle weakness, atrophy, and fasciculations. The disease was 
first described in 1869. ALS is named for its underlying pathophysiology. Amyotrophy 
refers to the atrophy of muscle fibres, which are denervated as their corresponding 
anterior horn cells degenerate. Lateral sclerosis refers to hardening of the anterior and 
lateral columns of the spinal cord as the motor neurons in these areas degenerate and are 
replaced by fibrous astrocytes (gliosis). Annual incidence of ALS is 1-2 per 100,000 
population. In a year, approximately 100 new patients with ALS are assessed at the 
Department of Neurology, Southern General Hospital that covers the Greater Glasgow 
Health Board region (verbal communication Dr R K H Petty, 2004). ALS may occur at 
any age, but peak age of onset is 55-75 years. Eventually, all deaths directly caused by 
ALS result from respiratory complications (141,142). This occurs primarily from 
progressive respiratory muscle weakness and hypercapnie respiratory failure. In patients 
with bulbar weakness, aspiration of secretions or food may occur and precipitate 
pneumonia resulting in further respiratory compromise. Mean duration of ALS from 
onset to ventilator dependence or death is 2-4 years. Most patients who opt for ventilatory 
support die within 5 years of diagnosis, but a small percentage (8-22%) survive 10 years.
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Pulmonary Function Tests:
Restrictive defect on lung function testing is common due to associated respiratory 
muscle weakness. Most patients at presentation tend to have abnormal lung function test 
even in absence of symptoms. Rate of decline in VC tends to be around - 3.5%/month
(143). The decline is steeper in patients who die early.
Respiratory Muscle Strength:
Respiratory muscle weakness is present in most patients with ALS at the time of 
diagnosis. SNIP is sensitive to pick up mild weakness and is a good predictor of 
progressive decline in muscle strength. It is easy to perform even in advanced disease
(144). In a study of 81 patients including those with bulbar involement, SNIP has been 
shown to have greater predictive power for the presence of hypercapnia compared to all 
the noninvasive tests including vital capacity (145). In those without bulbar involvement, 
sniff Pdi had the greatest predictive power in this study. However, in patients with bulbar 
involvement, none of the tests of respiratory muscle strength predicted hypercapnia and 
other investigators have also reported difficulty in reliably assessing strength in these 
patients.
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Sleep and Motor Neurone Disease:
REM sleep abnormalities precede daytime hypercapnia as in any other neuromuscular 
disease. Patients who are known to have diaphragmatic weakness as assessed during the 
daytime are particularly prone for this. The duration of REM sleep has been shown to be 
reduced in patients with diaphragm dysfunction. Obstructive apnoeas and hypopnoeas 
are almost never seen in ALS.
Arterial Blood Gases:
Venous bicarbonate and chloride have lately evoked interest (146) providing prognostic 
information regarding the respiratory status of these patients. This has opened avenues 
for domiciliary monitoring of MND patients. However it should be noted that this is only 
a useful marker of severe nocturnal hypoventilation and/or established hypercapnia and 
provides no useful information in early stages of the disease. Measurement of VC and 
mouth pressures is far more likely to provide such information in the initial stages.
In summary survival in MND is compromised by progressive respiratory muscle 
weakness leading to hypercapnie respiratory failure. Timely intervention with NIV has 
been shown to improve symptoms, survival and quality of life (130-132). Hence 
appropriate measures of respiratory muscle strength form an important assessment tool in 
these patients.
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1.9 PURPOSE OF THE STUDY
Various parameters of respiratory function such as vital capacity, sniff nasal inspiratory 
pressure are helpful in assessing the progression of the underlying disease and respiratory 
muscle weakness. But no single entity has been shown to predict the onset of ventilatory 
failure or mark the presence of underlying hypercapnia in this group of patients. 
Recently, bilateral anterior magnetic phrenic nerve stimulation (BAMPS) has been shown 
to be a useful nonvolitional way of assessing diaphragm strength. BAMPS has not been 
studied in MyD group and largely remains a research tool in patinets with MND. 
Identification of factors that would identify onset of ventilatory failure early would help 
in timely intervention with non-invasive ventilation and thereby improve quality of life 
and survival. The puipose of my research was:
1. To evaluate the role of routine pulmonary function tests and sleep studies in MyD and 
MND.
2. Evaluate the magnetic phrenic nerve stimulation teclinique in patients with MyD and 
MND as volitional tests can underestimate respiratory muscle strength.
3. To correlate the results of volitional and nonvolitional tests to assess respiratory 
muscle strength in MyD and MND.
4. To assess the relationship between peripheral and respiratory muscle strength, if any.
Most NMD patients are evaluated in clinics with the use of volitional assessment tools. 
Associated facial muscle weakness and/or bulbar dysfunction can be a confounding 
factor in these circumstances. The main objective of my research was to address the
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benefits of nonvolitional tests in preference to volitional tests in assessing respiratory 
muscle strength, if any. MyD and MND patients formed the two main groups of patients 
referred for respiratory assessment to our clinics and the studies were carried out in them.
I will now describe the materials used and the way the equipments were calibrated prior 
to each study.
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CHAPTER 2
MATERIALS AND GENERAL METHODOLOGY
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2.1 SUBJECT RECRUITMENT
Normal control subjects included staff from the respiratory laboratory and medical 
doctors from the respiratory wards at Gartnavel General Hospital.
Patients referred from the Departments of Neurology at Southern General Hospital, 
Medical Genetics Department at Yorkhill Hospital, Department of Respiratory Medicine 
at Gartnavel General Hospital and Glasgow Royal Infirmary were approached to take part 
in my studies. A Neurologist or a Medical Geneticist had evaluated all the patients and 
the diagnosis was confirmed by molecular genetics, muscle biopsy and/or 
electrophysiological studies where necessary.
Inclusion criteria: Patients with diagnosis of
1. Myotonic Dystrophy (MyD)
2. Motor Neurone Disease (MND)
Exclusion criteria:
1. Epilepsy
2. Neurosurgery with history of aneurysmal clips, cochlear implants
3. Cardiac pacemakers (147) or implanted defibrillators
4. Associated major cardiovascular or other respiratory conditions such as 
symptomatic airways obstiuction or pulmonary fibrosis
5. Pregnancy
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2.2 ETHICS APPROVAL
Ethical permission for each study was obtained from the Glasgow West Ethics 
Committee prior to commencement of the studies. Written information was given to all 
the subjects and written informed consent was obtained prior to the studies from all 
participants.
61
2.3 EQUIPMENT USED
2.3.1 Spirometry
Spirometers have come a long way since Hutchinson first described their use with a 
simple water sealed device (44). They form the basic screening tool in all respiratory 
laboratories for assessment of respiratory diseases. Vitalograph (fig 2.3.1.1) spirometer 
was used in my studies. This used Fleisch pneumotachograph for air flow measurements 
(accuracy ± 15L/sec, Maximal recordable volume 8L) and flow was integrated to give 
lung volumes. Subjects wore noseclip. Measurements were taken with the ‘open circuit 
method’. Subjects took a breath to maximal inhalation, then inserted the mouthpiece into 
the mouth with good seal from the lips around it and then blew out and continued 
exhalation to the end with continuous encouragement. FEVi, FVC and supine VC were 
routinely measured. For values to be reproducible, proper attention to technique was 
given. Best of 3 efforts was taken and the variability of the values obtained between the 
efforts had to be < 5%. Reference values were taken from Quanjer et al (149). Inter and 
intra observer variation tends to be less marked in computerised analysis. The variability 
has been well studied in a large epidemiological study for diagnosis of COPD by Spanish 
investigators (150). Amongst seven investigators, intraindividual coefficient of variation 
was about 4% for FEVi, FVC and FEV|/FVC and interobserver coefficients of 
correlation were 0.99 for FEVi and FVC measurements and 0.958 for FEVi/FVC (151), 
This amount of variablility is generally considered acceptable in research studies. 
Quality control data was maintained in the laboratory for the duration of the study.
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m
Fig 2.3.1.1: Vitalograph spirometer.
2.3.2 Transducers and Amplifiers: (Fig 2.3.2.1)
g
9
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Fig 2.3.2.1: Transducer module (on the right) attached through a universal interface 
module to the MP 150 recording system (on the left).
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The pressure transducers measure a pressure applied to one or both sides of their 
diapln'agm. All the pressure measurements were made using a 4-channel pressure module 
built by the Biomedical Engineering Department at the South Glasgow Hospitals NHS 
Tmst. It was designed to be added on to the Biopac MP 150 system through which all 
the recordings were carried out. The pressure ranges built in were within the estimate of 
clinical usage (± 350 cm H2O). All the signals were pre amplified, electrical signals 
passed through an analog-digital (A-D) board to be recorded using the MP 150 system.
Linearity of the pressure transducers (measuring Pino, Poes, Pgas) was checked against 
Bio-Tek pressure meter (BIO-TEK instmments Inc, Winooski, VT, USA) as shown in fig 
2.3.2.2.
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Fig 2.3.2.2: Shows the pressure transducers to be linear over -250 to +250 cm H2O 
pressure that is well within the clinically measured range.
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2.3.3 Mouth Pressure Equipment:
Static Inspiratory and Expiratory Mouth Pressures:
Fig 2.3.3.1: Modified cylinder with attached flanged mouthpiece to measure mouth 
pressure.
Mouth pressures were measured using a cylinder with a modified three way valve system 
(fig 2.3.3.1) while each subject was seated comfortably and wore a nose clip. The stem 
was 31.5cm in length with an internal diameter of 2.3cm. A small hole (diameter 2mm) 
was created proximal to the occlusion that could temporarily be created using the 3-way 
valve. This was to prevent cheek pressures from buccal contraction contributing towards 
measurements during the expiratory manoeuvres and to keep the glottis open during 
inspiratory efforts (86). The subject held the metal cylinder in his hand and performed 
the inspiratory/expiratory manoeuvre by keeping the flanged mouthpiece tightly sealed 
between the lips to prevent any perioral leaks. Since associated facial muscle weakness 
is commoner in the group of subjects 1 studied, flanged mouthpiece was used. Patients 
were also encouraged to support their cheeks with the other hand to minimise leaks. 
Assistance was given to hold the metal cylinder in those patients who were unable to do 
so on their own. The metal cylinder was connected through rubber tubing to the pressure
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transducer-ampHfier system. The nonnal values were established for our laboratory 
(appendix I and II). The values were averaged for the first second from initiation of the 
effort to obtain the sustained pressure for one second (fig 2.3.3.2 & fig 2.3.3.3). Subjects 
were given constant encouragement to obtain maximal effort to sustain for about 2 sec. 
They could visualise their effort on the computer screen. Best of 4 to 6 efforts was taken 
as the value of maximal inspiratory (MIP) and expiratory pressure (MEP). If the last 
measurement obtained was the highest, further measurements were carried out.
Peak Pressure
Isec
100 cm H2O
0 cm H2O
Fig 2.3.3.2: A typical MEP measurement.
Isec
— Peak Pressure
0 cm H2O
100 cm H2O 
Fig 2 3 3 3 :  A  typical MIP measurement.
Ringvist et al have shown that the highest maximal expiratory pressures were obtained at 
greater than 70% of TLC and the highest maximal inspiratory pressures were at volumes
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less than 40-50% of TLC (86). As per convention, MIP was measured from RV and 
MEP from TLC.
Pressure measured at the mouth (Pmo) is a combination of respiratory muscle pressure 
(Pmus) and the elastic recoil of the lungs and chest wall (Prs). At FRC Prs is zero and 
hence Pmo = Pmus and that is the advantage of measuring mouth pressures from FRC as 
the negative recoil pressure of the respiratory system is excluded. However MIP was 
measured from RV in these studies when Prs may be approximately -30cm H2O. At 
MEP measured at TLC, again Prs can be up to + 40 cm H2O (152). The advantage of 
MEP measured from TLC is that expiratory muscles are at optimal length to generate 
force. Many studies done to date normally have not taken into account the contribution 
of Prs and this usual convention was followed in my experiments.
In my studies, MIP < 80cm H2O, MEP < 90cm H2O and SNIP < 70cm H2O were 
considered to be significantly reduced on the basis of available literature and the normal 
values obtained in our lab (appendix I,II).
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Sniff Nasal Inspiratory Pressure: (fig 2.3.3.4)
Fig 2.3.3.4: SNIP measured with the nasal bung made of dental impression material, 
connected through a tubing to the pressure transducer.
SNIP is a non-invasive measure of sniff Poes. It is characterised by an increase in the 
lung volume with distortion of the chest wall. It often reflects inspiratory muscle strength 
better than MIP. However studies have shown that level of agreement between SNIP and 
MIP is low (153) and hence these measurements are likely to be complementary rather 
than substitutive. SNIP was measured through a nasal bung occluding one nostril whilst 
short sharp sniff manoeuvre was performed through the other. The nasal bung was made 
from dental impression material. It was connected to the pressure transducer through a 
96 cm polyethylene catheter (internal diameter 1.3mm). Measurements were made in 
sitting posture from RV and best of 4-6 sniff efforts were taken as the maximal SNIP. 
Each sniff manoeuvre was separated by 30 sec. Subjects were given constant 
encouragement and were allowed to view their effort on the computer. The total duration 
of the effort should have been less than half a second to be suitable for analysis.
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2.3.4 Balloon Catheters (fig 2.3.4.1)
Fig 2.3.4.1: Oesophageal balloon catheter.
Liquid filled catheters (154) and catheter mounted microtransducers, fibreoptic sensors 
can all be used for the measurement of the oesophageal pressure. Balloon catheter 
system was used in my studies (155). Ackrad Laboratories, Cranford, manufactured the 
set I used. This radio opaque latex-free set contained an 86 cm closed end catheter with a
9.5 cm balloon with an uninflated circumference of 1cm placed 5cm proximal to the 
catheter tip. The internal diameter of the catheter was 1.3mm and the exterior was 2mm. 
At the distal end within the balloon were 4 parallel placed holes. There was a stylet with 
Y connector to aid placement of the catheter. Two catheters were inserted through the 
nose after application of 10 to 15 ml 2% lignocaine gel (Biorex Laboratories, London, 
UK) to the nostril. Once the catheters were advanced to the hypopharynx, swallowing of 
the catheters was aided by sipping cold water through a straw. Most subjects tolerated 
this reasonably well. Both catheters were passed to the stomach, the position confirmed 
by positive deflection on the pressure tracings during inspiration. Then one of the 
catheters was withdrawn to the oesophagogastric junction -  which was identified by the
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change in pressure tracing to negative deflection. The catheter was withdrawn by a 
further 10 cm so that the balloon was positioned in mid oesophagus. The stylet from the 
catheter was then removed. Most subjects felt the tubes to be more tolerable once the 
stylet was removed. The catheters were secured with tape. All subjects were instmcted 
not to eat or drink anything until numbness subsided to avoid aspiration. Studies have 
shown that the Poes and Pgas represent pleural and abdominal pressures respectively 
(156,157) and the resultant arithmetic difference between them, Pdi, remains the gold 
standard for measuring diaphragm contractility.
The catheter was then connected to the pressure transducer-amplifler system through the 
extension tubes (96 cm in length and internal diameter 1.3 mm) provided with the 
catheter set via a 3-way stopcock to allow patients to move their heads freely. With the 
stopcock open to an attached 10 ml syringe, all the air from the balloon was evacuated by 
pulling back on the plunger and then allowing the plunger to return to a non-vacuum 
position. About 5 ml air was injected to smooth out folds within the balloon. The 
oesophageal balloon was inflated leaving behind 0.5 ml air and the stomach balloon with 
2 ml of air. The volume of air was decided depending on the available literature and the 
pressure volume characteristics of the balloon as carried out in our laboratory (fig 
2.3.4.2).
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Fig 2.3.4.2: Pressure volume characteristics were determined at atmospheric pressure 
after the balloon was emptied and increments of 0.1 ml volume air was added with a 
syringe and the pressure was recorded after each incremental addition. The pressure 
volume curve of the balloon catheter system at atmospheric pressure was flat between 0.4 
-  2.4ml of air; ie., there was only negligible change in balloon pressure when air was 
added in this range. Outside the body the balloon required 0.4 ml of air to restore 
pressure to zero.
The positions of the balloon catheters were confirmed by measuring the mouth pressure 
whilst the subject took a slow inspiration against a closed shutter (158). The position was 
considered satisfactory if the mouth and oesophageal pressures were parallel. After 
positioning the balloon catheters, tracheal artefact was looked for. Valsalva and Müller 
manoeuvres normally provide only a small lung volume change when glottis is open and 
the airway is obstmcted beyond the pressure tap for mouth pressures. Then the pressure 
difference from the mouth to oesophagus approximates transpulmonary pressure and any 
pressure change will also be small. If upper part of balloon was placed behind the 
proximal trachea, transpulmonary pressure changes will be marked by larger increase 
during Valsalva manoeuvre and decrease during Müller manoeuvre. This is due to
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impingement of the trachea against the oesophagus. During Valsalva manoeuvre, trachea 
is pulled away from the oesophagus making oesophageal pressure change to be in a more 
negative direction. During Müller manoeuvre the trachea is forced against the 
oesophagus causing oesophageal pressure to increase markedly. If this artefact was 
present the oesophageal pressure would change with head position, extension causing 
negative deflection and flexion positive. Finally, the position was adjusted to minimise 
cardiac pulsations (159).
Oesophageal spasm can occur nearer to TLC and peristaltic waves lasting for 2-5 sec 
were monitored for. The peristaltic waves tend to be more frequent when the balloon is 
in the lower oesophagus and during swallowing and before mealtimes (160).
‘Pop test’ (161, fig 2.3.4.3) was used to measure the response time of each catheter -  
connecting tube -  transducer -amplifier - recorder system. The balloon catheter was 
placed in a larger pressurised condom (pressure was raised by insufflation of air via a 
cylinder). The pressure was maintained at 100 cm H2O and a square wave fall in pressure 
was created by bursting the condom with a red hot needle. 90-10% decay time (Dt) for 
pressure was 0.019 sec. The frequency response of the system used in my thesis was 
calculated using the equation Fr = (3*Dt)"\ ie., (3*0.019) = 17.5 Hz.
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100 cm H2O
19 ms 0 cm H2O
Fig 2.3.4.3: Frequency response of the system.
A static in vitro test of the balloon transducer amplifier computer system was also 
conducted by comparing the pressure inside a sealed glass bell jar (fig 2.3.4.4) measured 
directly with bio-tek meter with that obtained using the transducer-amplifier-computer 
connected to balloons containing 0.5 and 2 ml air. The pressure changes were linear and 
accurate over -200 to +250 cm FI2O (fig 2.3.4.5).
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Fig 2.3.4.4: Schematic representation of in vitro test of the balloon transducer amplifier 
computer system.
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Fig 2.3.4.S: In vitro test of balloon transducer amplifier computer system.
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2.3.5 Magnetic Phrenic Nerve Stimulation
Duchenne introduced the technique of phrenic nerve stimulation. However quantification 
of the diaphragm contraction was not carried out till 1970’s (162). Unilateral or bilateral 
percutaneous phrenic nerve stimulation can be carried out by creating an electric current 
via bipolar electrodes placed over the anterolateral aspect of the neck (163). Until 
recently electrical stimulation (ES) of the phrenic nerve was the preferred choice to study 
the electrical activity of the diapliragm. It is a highly skilled technique and not used 
routinely in clinical practice. The stimulation can be painful and finding the nerve root 
with the electrode, which is crucial, can be time consuming. When the values are low, it 
is difficult to be certain if the stimulation was submaximal. All these factors contribute to 
the widely reported normal range of TwPdi with ES ->  8.8-33 cm H2 O. More recently 
magnetic plirenic neiwe stimulation has been shown to be useful to study the 
electrophysiological properties of the respiratory muscles, diaphragm in particular. The 
advantage of this technique is that it is relatively painless, precise localisation of the 
nerve is not required as with ES and it has also been used successfully in intensive care 
settings.
Introduction to Magnetic Stimulation: Michael Faraday in 1831 first described 
electromagnetic induction at the Royal Institution of Great Britain. He wound two 
magnetic coils on an iron ring and found that whenever the coil on one side was 
connected to a battery, electrical current passed through the coil on the other side. A 
change in the magnetic field from the first coil induced a current in the second coil. 
With time it has been realised that if sufficient primary current exists the iron ring can be
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dispensed with as it only improved the coupling efficiency (fig 2.3.5.1). This forms the 
basis of non-invasive magnetic peripheral nerve stimulation in clinical practice. Poison et 
al produced the first magnetic stimulator capable of peripheral stimulation and recorded 
the muscle evoked potential (164). The intense magnetic fields created by stimulation 
penetrate clothing, soft tissue and bone to reach neural tissue. They preferentially 
activate the larger fibres, avoiding smaller fibres that mediate pain (165).
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Fig 2.3.5.1: Magnetic Stimuli created by passing strong electrical current through a coil 
of wire (Reproduced with permission from Reza Jalinous -  Guide to magnetic 
stimulation).
The magnetic nerve stimulators consist of two distinct parts: a high current pulse 
generator and a stimulating coil (fig 2.3.5.2). Magstim 200 stimulator (Magstim 
Company Limited, Whitland, Dyfed, Wales) was used in my study. The high current 
pulse generator produces magnetic pulses with field strengths of 1 tesla and pulse 
duration of 1msec (manufacturer’s information). Although the energy released is small, 
the duration of discharge is short and hence the power (energy/unit time) is considerable. 
When a magstim receives a trigger input signal, the stored energy in the capacitor is
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discharged and transferred to the stimulating coil that contains wound insulated copper 
coils in a plastic case.
Fig 2.3.5.2: Magstim stimulators with figure of 8 coils.
The discharge switch contains an electronic device called thyristor which conducts 
current in only one direction. Magstim 200 thus being monophasic has reduced heat 
dissipation in the coil and fewer stimulus artefacts.
The stimulating coil used was a 70 mm double coil (butterfly or figure of 8) in which the 
current induced was maximal directly under its centre where the two windings meet. The 
current flow in one is opposite to the flow in the other which may explain the site of 
maximal current.
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Cervical magnetic phrenic nerve stimulation: Similowski et al (166) reported this 
technique to assess nonvolitional diaphragm strength in 1989. The stimulation is carried 
out by placing a circular 90 mm coil over the spinous process of C7 whilst the neck is in 
a flexed position to allow bilateral stimulation of the phrenic nerve roots.
Bilateral anterior magnetic phrenic nerve stimulation (BAMPS) was employed in my 
study as it is more likely to be supramaximal (167) compared to the cervical approach 
and also the contribution from ribcage muscle contraction towards TwPdi is less (168). 
Supramaximal stimulation implies that a further increase in stimulus intensity does not 
result any further increments in tension generation. Stimulations were earned out on 
subjects in a seated position after at least 20 min of rest to avoid twitch potentiation 
(169). The two coils were placed on either side of the neck at the posterior border of the 
sternocleidomastoid muscle at the level of the cricoid cartilage in sitting posture. The two 
Magstim 200 stimulators were connected so they fired simultaneously and at least 30 sec 
was left between stimulations. Each subject received 4 to 6 stimulations. Stimulations 
were done at end expiration, which was verified by careful observation of the 
oesophageal tracing (170). Previously researchers have used abdominal binding but this 
can markedly increase TwPdi although not have any effect on sniff Pdi (171). The 
abdomen was unbounded in my studies.
Whilst doing off-line calculation of the tracings, particular attention was paid to the 
quality of the twitches. Only twitches with a peak within 200m sec from the stimulation 
were included for analysis. Twitch responses where the Poes varied more than 1 cm H2O
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immediately prior to the realisation of the twitches were ignored. So were the 
stimulations performed during swallowing or oesophageal peristalsis.
It has been shown that postprandial state increases TwPdi substantially (172) and I had 
asked all my subjects not to eat anything for at least 2 hours prior to arriving for the tests.
Table 2.3.5.1: Summary of the differences between electrical and plirenic nerve 
stimulation (173):
Electrical Stimulation Magnetic Stimulation
Stimulation Technique Stimulates phrenic nerve Stimulates phrenic nerve as
selectively well as cervical nerve roots
Technical Expertise Necessary Not necessary
Associated Pain + Relatively painless
Poes - Higher than with ES
TwPdi 8-33 cm H2O Narrower range
Transdiapliragmatic pressure (Pdi), the difference between Pgas and Poes represents the 
force generated by the diaphragm (174). Poes and Pgas were measured directly and Pdi 
was calculated in real time by the online subtraction of Poes from Pgas.
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Magnetic stimulus applied end expiration
TwPdi-21 .3  cm H2O
^ Pgas -9.2 cm H2O
Poes -12.1 cm H2O
Fig 2.3.5.3; A typical pressure tracing following magnetic phrenic nerve stimulation.
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2.3.6 Pneumotachograph for flow measurements (Fig 2.3.6.1)
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Fig 2.3.6.1: Hans Rudolf heated pneumotachometer.
Hans Rudolf heated pneumotachometer (model 3700 series) was used in my studies to 
make all the flow measurements. The principle involves gas flow across two fixed 
resistors and a transducer measures the pressure drop from one end to the other and this is 
proportional to the gas flow as long as the flow is laminar. A heater was used to 
minimise condensation of the expired gas on the element. The flow signal was integrated 
to obtain tidal volume measurements. The flow measurements were mostly used to 
calculate the dynamic compliance of the lung.
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2.3.7 Compliance of the Lung
Compliance of the respiratory system is a measure of the distensibility of the lung. It is 
the inverse of the elasticity or the elastic recoil. The total compliance of the respiratory 
system is a combination of the compliance due to that of the lung and the chest wall. 
Since they are in parallel, they can all be linked by the equation,
i  = _______ :___________+ ____________L
Total Compliance Compliance of the lung Compliance of the chest wall
Total compliance in a normal person at FRC is about O.lL/cm H2O and that of the lung 
and chest wall about 0.2 L/cm H2O.
The compliance of both lungs together will be additive as they run parallel.
Dynamic compliance of the lung was measured in my studies and this 
represents the pressure volume characteristics during tidal breathing. At low breathing 
frequencies, dynamic compliance is usually equal to the static compliance. In patients 
with increased resistance to air flow at higher breathing frequencies, the ratio of dynamic 
to static compliance falls below unity.
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Fig 2,3.7,1a: The dynamic compliance was calculated by dividing change in volume by 
change in Poes at points of zero flow and by averaging 5-15 consecutive breaths.
Fig 2.3.7.2b: Represents the raw graph demonstrating points of zero flow (block arrows). 
Difference in the direction of the integrated volume depicted in the figures is due to 
change of flow in the flow head of the pneumotachogiaph.
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Since dynamic compliance is frequency dependent, comparative measurements were 
matched for respiratory rate ( 175).
2.3.8 Strain Gauge for Quadriceps Strength Assessment
Dynamometers are commonly used to measure muscle strength although the variability 
of these tools is quite high (176). Any measurement of muscle force assessment are 
affected by the type of the equipment used, knee flexion angles and underlying disease 
condition. Since motor neurone disease can affect muscle groups patchily, peripheral 
muscle strength was not assessed in subjects with this condition.
A strain gauge system on a T piece was used in my studies to assess quadriceps muscle 
strength. The strain gauge was connected through a pre-stretched cord to an ankle band. 
Subjects were tested in lying posture and were asked to pull hard against the cord (fig 
2.3.8.1), 5 to 10 attempts were made for each subject and the maximal value was taken as 
the maximal voluntary contraction (MVC) of the quadriceps muscle.
Fig 2.3.8.1: Strain gauge system used to measure peripheral muscle strength.
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Linearity of the strain gauge system was checked (fig 2.3.8.2).
M m «  K g s
Fig 2.3.S.2: Demonstrates linearity of the strain gauge system at a gain of 100, which was 
used for study purposes.
2.4 Calibration of the Equipment
Electrical equipments require time to warm up during which the output from the 
transducers and amplifiers can drift. To obtain accurate signals able to discriminate small 
changes, all equipment was regularly calibrated. I used the two-point calibration system 
recording a zero signal (at atmospheric pressure) and a signal at one extreme of the range 
measured prior to each study.
The spirometer was calibrated using a three-litre syringe (with an accuracy of ±  15ml, 
Vitalograph Ltd, Buckinghamshire, England, UK) and a two-point calibration technique 
with zero as the baseline point and three litres as the actual value. The variability had to 
be < 3% to be acceptable.
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The pressure transducer-amplifier system was calibrated prior to each study using the 
portable DPM III Universal biometer (BIO-TEK instruments Inc., Winooski, VT, USA). 
Atmospheric pressure (defined as 0) was used as one value and the other value was 
obtained by creating either a negative (for transducer measuring Pmo/MIP/SNIP) or 
positive (for transducer measuring MEP/Pgas) pressure using a 10ml syringe in a closed 
circuit with the transducer and the biometer. The universal biometer, flow meters of the 
air regulator and the Platon rotameter were checked for accuracy using the Timiter 
Calibration Analyser (series RT-200, Timiter Instrument Corportaion, Lancaster, PA -  
tig 2.4.1 ) on a periodical basis (every 6 months).
Fig 2.4.1: Timiter series calibration analyser.
The pneumotachograph was calibrated with flows in both inspiratory and expiratory 
directions. Airflow was generated via a pressurised air cylinder and controlled by a 
rotameter (Paton flow control, Basingstoke, UK and this covered flow range from 0.06 to 
100 L/min air). Calibration was carried out at ambient temperature, again using the 2- 
point system.
The strain gauge system used to measure MVC was calibrated using two known weights 
(0kg, 25kg) prior to each study.
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CHAPTERS
INDIVIDUAL EXPERIMENTS AND RESULTS
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3.1 Pulmonary Function Tests in MyD and MND
3.1.1 Hypotheses:
1. Simple spirometry needs to be supplemented with mouth pressures to give better 
picture about underlying respiratory muscle weakness in MyD and MND.
2. Routine measurement of full pulmonary function tests would be useful in monitoring 
these patients.
3.1.2 Study Design:
In 20 MyD and 5 MND patients we evaluated dynamic lung volumes, relation between 
FEVs and F VC, correlation between F VC, TLC, RV, diffusion capacity and mouth 
pressures (MIP<80cm H2O and MEP<90 cm H2O were considered to be significantly 
reduced). There were 4 patients without any particular respiratory symptoms (2 with 
MND and 2 with MyD) and the remaining 21 had disturbed sleep pattern, excessive 
sleepiness, breathlessness on exertion and tiredness when directly enquired.
All patients attended the respiratory laboratory in the morning to minimise the diurnal 
effect on pulmonary function testing (177). Height and weight were recorded to obtain 
body mass index [BMI in kg/m^ = weight in kg / height in m ]^ (178). Epworth sleepiness 
scale score was obtained (179, appendix III). Twenty patients underwent lung volume 
measurement using the Medisoft HYPAIR Compact Helium dilution technique. Five 
patients had body plethysmography in place of Helium dilution technique using 
Pulmolink system (Medisoft 5500 model with EXPAIR software). This can give higher
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values for FRC (thoracic gas volume) as it takes into account any trapped gas. This was 
used due to technical problems with Helium dilution technique on the day patients 
attended the laboratory. Sitting/standing VC and supine VC were measmed with a 
Vitalograph spirometer (Bucks, UK).
3.1.3 Technical outline:
Helium Dilution Techniqne (180): Subjects breathed through a closed circuit, a gas 
mixture containing insoluble Helium (14% He, 24.5% oxygen balanced with nitrogen). 
During rebreathing CO2 was absorbed and oxygen added continuously to maintain 
constant overall volume of the system. Normally He equilibration is taken to be 
complete when the concentration of He is < 0.02% over BOsec.
FRC was calculated from the formula:
Vi*FiHe = V2 *F2He
= (V,+FRC+VD)*F2He
FRC+VD = VifFiHe-F7He) L. ATPS (which is converted to BTPS).
F2He
Where V 1 - Known volume of the gas mixture
F|He - Initial fractional concentration of He
FiHe - Equilibration concentration of He
VD - Dead Space (of the equipment + anatomical dead space)
At the end of the procedure subjects took a deep breath in to give inspiratory capacity IC. 
FRC+IC = TLC.
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The body plethysmograph employs Boyle’s law, which states that for a closed container
at constant temperature, the pressure times the volume is constant. The subjects sat in the
‘box’ and breathed through a mouthpiece. The tubing from this contained a sidearm
connected to a pressure transducer to measure mouth pressure. At relaxed end expiration,
mouth and alveolar' pressure equals atmospheric pressure (Pi). Vj is the unknown FRC.
A second pressure monitor measured box pressure. Pneumotachograph was used to
measure airflow. Once a normal breathing pattern was established the operator closed the
shutter in the airway at the end of normal expiration. The subjects took a breath in
against the closed airway. Here the chest continued to expand and box pressure increased
because of the volume of air in the box decreased by the amount the patient’s chest
volume increased (AV). The true box volume wliich is the volume of the plethysmograph
minus the volume occupied by the patient can not be easily deteiinined and hence the
plethysmograph was calibrated with the patient in it by injecting known volumes of air
into the plethysmograph and determining the increase in pressure.
Pl*V, =P2*V2
= (P r A P)*(Vi + A V)
Vi = P|*A V/AP
Product of A VA P is ignored as the value tends to be very small.
A V is a function of the change in the box pressure that can be measured easily.
A P -  Change in the mouth pressure (Pi) after full inspiration.
Pi -  Initial mouth pressure at end expiration, which is the barometric pressure.
V 1 -  Represents the thoracic gas volume at end expiration.
Carbon monoxide Diffusion Capacity (TLCO) was measured using single breath 
technique (181). Subjects breathed rapidly from RV to TLC via a reseiwoir bag 
containing a mixture of 0.28% CO + 9% He + 19% O2 balanced with nitrogen. The
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breath was held for lOsec at maximal inspiration and then a rapid and complete 
exhalation was made. The rate of transfer of CO (kCO) was measured at full lung 
inflation and was corrected for the haemoglobin concentration (182). TLCO was 
calculated as the multiple of kCO and alveolar volume divided by the barometric pressure 
(Pb).
3.1.4 Results:
There were 8 former and 1 current smoker in the group. Subject details and lung 
volumes are summarised in Tab 3.1.4.1-3.1.4.4. Results are expressed as mean (95% Cl), 
Table 3.1.4.1 Patient subgroups:
Patients with reduced 
FVC < 80% n = 14
Patients with normal FVC > 
80% n = 11
Male:Female Male: Female
MyD 6:5 5:4
MND 3:0 1:1
Table 3.1.4.2 Demographic details:
Patients with reduced 
FVC <80% n = 14
Patients with normal 
FVC > 80% n = 11
Age (years) 44.5 (38.7-50.3) 41.1 (34.6-47.6)
ESS 9.1 (6.8-11.3) 13.1 (10.7-15.5)
Body Mass Index (kg/m^) 27.8 (24.5-31.2) 25.4 (23.8-27.0)
Table 3.1.4.3 Dynamic Lung Volumes: * p < 0.05
Patients with reduced FVC < 80% 
n — 14
Patients with normal FVC > 80% 
n = 11
% Predicted FEV \ 59.0 (51.9-66.1) 94.2 (86.2-102.2)*
% Predicted FVC 59.3 (52.8-65.9) 94.2 (86.2-102.2)*
FEVi/FVC 101.7 (99.7-103.6) 95.4 (89.9-100.9)
% fall in supine VC 11.7 (7.5-15.9) 6.7 (4.1-9.2)
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Mouth pressures in graphical representation
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*p = 0.048
Fig 3.1.4.1: Mouth pressures in MyD and MND. Though both MIP and M EP tended to be 
reduced, only MEP showed a significant trend in subjects w ith FVC < 80% predicted.
Table 3.1.4.4 Static Lung Volumes:
Patients with reduced FVC <80% 
n = 14
Patients with normal FVC > 80% 
n = 11 p value
% Predicted FRC 81.3 (66.2-96.4) 102.8 (93.1-112.5)* 0.013
% Predicted ERV 51.7(44.4-59.1) 115.6 (97.1-134.1)* 0.0001
% Predicted RV 107.4(85.3-129.5) 94.4 (81.4-107.3) 0.62
% Predicted TLC 75.7 (66.6-84.9) 97.7 (92.3-103.1)* 0.007
% Predicted TLCO 68.6 (63.3-73.8) 84.1(76.7-91.4)* 0.02
% Predicted KCO 109.9 (99.2-120.6) 92.2 (82.6-101.8) 0.10
♦ p < 0.05
Correlation between static, dynamic lung volumes and mouth pressures is depicted in Fig
3.1.4.2 to 3.1.4.8.
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Fig 3.1.4.2: Correlation between FEV, and FVC.
Only two patients who were previous smokers had FEV,/FVC ratio < 80% predicted. 
Otherwise the reduction in FEV, tracked closely to that of FVC (fig 3.1.4.2) showing the 
well described restrictive defect. Though the percent supine fall in supine vital capacity 
was higher in patients with low MIP and FVC, this did not reach statistical significance.
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Fig 3.1.4.3: Correlation between FVC and TLC (r=0.7, p<0.05). There were 2 patients 
with TLC > 100% predicted when FVC was reduced. One was a patient with MND with 
significant smoking history and FEVi/FVC ratio was < 80% signifying airflow 
obstruction. The other subject was one with MyD with 10 pack year history of smoking 
but the spirometry was restrictive in nature. This patient had lung volume estimation by 
body plethysmograph.
MIP vs FVC
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Fig 3.1.4.4: Correlation between FVC and MIP (r=0.54, p<0.05). This graph demonstrates low 
values of MIP even when FVC is within the normal range.
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Fig 3.1.4.5: Correlation between FVC and MEP (i-0.42, p~0.0005). Again, there is a scattter but 
this graph highlights that MEP as with MIP is reduced in a group of patients when the FVC is 
within the predicted range.
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Fig 3.1.4.6: Correlation between TLC and MIP (r=0.23, p~0.27). The scatter aronnd the axis was 
greater compared to the relation between FVC and MIP (weaker correlation). Again there were 
patients with normal TLC with reduced mouth pressures as seen with FVC.
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Fig 3.1.4.7: Correlation between RV and MEP (r=-0.2, p=0.4).
99
In 10 out of 11 patients (90.9%) with noiinal FVC, MIP and/or MEP were reduced 
suggesting significant inspiratory and/or expiratory muscle weakness. The ratio of % 
RV/TLC coiTelated significantly with percent predicted RV (i-0.4, p=0.02), as a measure 
of air trapping, which is an indirect evidence of expiratory muscle weakness. However 
correlation between MEP and %RV, %RV/TLC and % ERV was weak.
% Pred TLCO v s  % Pred FVC
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Fig 3.1.4.8: Correlation between FVC and % TLCO (i-0.53, p=0.006). There were 4 
patients (36.7%, 3 with MyD and 1 with MND) with reduced % TLCO when FVC was 
preserved. Mouth pressures were invariably reduced in these patients.
Correlation between FVC and KCO again was not strong though significant (i--0.47 and
p=0.02).
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3.1.5 Discussion:
In our group of MyD and MND patients with minimal symptoms, 56% showed reduction 
in both FVC and mouth pressures. However 90.9% of patients with preserved vital 
capacity showed reduced mouth pressures. Vital capacity was a good marker for TLC, 
FRC, ERV and TLCO. MEP correlated poorly with residual volume. This study 
reiterates the importance of basic spirometry to provide useful information at the outset in 
the assessment of this group of patients. MIP, MEP values were quite reduced in spite of 
ensuring adequate seal during the procedure and making certain that there were no leaks 
within the system. Again this is supported by the values obtained for ‘normal subjects’ 
within our laboratory using the same methodology (appendix I,II). The relation between 
FVC and MIP is curvilinear (183) and hence the fall in mouth pressure precedes lung 
volume change. This could partly explain the significant number of patients with low 
mouth pressures and preserved FVC and also highlights the importance for measuring 
mouth pressures along with simple spirometry in this group of patients. There is a great 
between- and within individual variation for mouth pressures and this could contribute to 
the low values of MIP and MEP with reasonably preserved FVC in our group of patients. 
Thirdly, use of flanged mouth piece gives lower and more variable values compared to a 
tube mouth piece especially in patients with buccal muscle weakness (184) which would 
contribute to low mouth pressures in our patients.
Static lung volumes and diffusion capacity did not yield any further infoimation that 
could not be predicted from baseline spirometry. For routine monitoring this also avoids
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neuromuscular disease patients to come into the laboratory for detailed assessments. 
Simple spirometry and mouth pressures carried out either in the outpatient clinics or at 
home by trained staff provides useful information that could guide further management of 
patients with neuromuscular and chest wall disorders. It used to be thought that 
respiratory muscle weakness is associated with reduced TLCO and increased KCO 
showing the well described ‘extra pulmonary restriction’. However in a landmark study 
by Hart et al (185), relation between lung volumes, respiratory muscle weakness and 
diffusion capacity was explored. It was shown that the KCO varies depending on the 
volume and extent of inspiratory/expiratory muscle involvement and in combined 
weakness KCO was even normal or reduced indicating abnormalities of lung parenchyma 
or vasculature. There were patients with reduced TLCO and KCO in our group of 
patients but as invasive respiratory muscle tests were not earned out, a closer 
examination of this relationship was not possible.
It is generally accepted that < 25% fall in supine vital capacity is a marker of significant 
diaphragm weakness. In our group of patients, even in the face of severe reduction in 
MIP this was an uncommon event. This suggests that the sensitivity of supine vital 
capacity is quite weak and if clinically indicated, further tests of diaphragm strength 
should be carried out to confirm the diagnosis. However in this set of studies, SNIP or 
Pdi measurements were not carried out. This is further discussed in chapter 5.1.
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3.1.6 Conclusions:
It was noted that mouth pressures were low in patients even when their FVC and TLC 
were within the predicted range and this supports our hypothesis that ‘mouth pressures 
should always supplement routine lung function tests in assessment for respiratory 
muscle weakness’. No extra information was gathered by routine monitoring of static 
lung volumes and diffusion capacity.
The difficulty remains for the clinician to determine whether low mouth 
pressures/volitional tests equate to ‘true reduction in respiratory muscle strength’ and this 
is explored in further experiments.
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3.2 Sleep Studies in MyD and MND 
3.2.1 Hypothesis:
1, Routine sleep studies would help to identify a group of MyD and MND patients with 
significant SRBD early that would benefit from interventions such as NIV.
Our secondary aims were to
i) Identify common symptoms of presentation.
ii) Define the prevalence of SRBD in our group of patients.
iii) Relate daytime pulmonary function tests to nocturnal parameters.
iv) Identify the practicality of different sleep study systems.
3.2.2 Study Design
Number of patients: 37
Table 3.2.2.1: Patient characteristics.
MyD n=25
(15 Male: 10 Female)
MND n=12
(11 Male: 1 Female)
Age (years) 40.0 (35.9-44.1) 59.2 (45.1-73.2)
BMI (kg/m )^ 26.1 (22.8-29.3) 24.5 (21.2-27.7)
ESS 11.0 (8.8-13.2) 4.6 (2.9-Ô.3)
Patients should have had at least one symptom suggestive of respiratory muscle weakness 
or nocturnal hypoventilation to be included in the study. They were specifically asked
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about daytime sleepiness, breathlessness, orthopnoea, easy fatigability, snoring, apnoea, 
disturbed sleep, morning headaches and recuixent lower respiratory tract infections.
All the patients were asked to complete the Epworth Sleepiness Scale (ESS) as a measure 
of sleepiness (179, appendix III). They subsequently underwent full polysomnography or 
overnight oximetry in hospital followed by assessment of spirometry, supine vital 
capacity, mouth pressures (MIP < 80cm H2O, MEP < 90cm H2O and SNIP < 70cm H2O 
were considered to be significantly reduced) and awake arterial blood gases in the 
morning. Patients who preferred not to come into the hospital were called into the 
Respiratory Laboratory to have lung function tests and were given a wrist pulse oximeter 
to take home for overnight monitoring.
Dynamic lung volumes were measured using a spirometer (Vitalograph; Bucks, UK) and 
reference values taken from the European Community for Steel and Coal (149). Maximal 
Inspiratory pressure (MIP) was measured from total lung capacity and Maximal 
Expiratory pressure (MEP) from residual volume according to standard criteria 
(152,186).
Polysomnography: Sixteen-channel polysomnography (Sensormedics Alpha or Alice 3 
vl.2) was carried out in 20 subjects (18 MyD and 2 MND) and that included 
electroencephalogram (EEC), electrooculogram, chin electromyogram (EMC), airflow (3 
port thennistor), electrocardiogram (ECG), respiratory movements of chest and abdomen
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(using inductance plethysmography), microphone to identify snoring and pulse oximetry. 
EEG (C4-A1, C3-A2) was used to score awakenings and sleep stages according to 
standard criteria (187). Computer scoring was reviewed by an experienced technician 
and rescored manually if required. Sleep efficiency (SE) was derived as the ratio of total 
sleep time (TST) to time in bed. An apnoea was defined as reduction in airflow to < 30% 
from baseline associated with 4% reduction in oxygen saturation (Sp02) or complete 
cessation of flow lasting at least 10 sec. A hypopnoea was scored when the airflow 
reduced to < 50% from baseline associated with 4% drop in SpOz. An apnoea was 
considered to be obstructive when the thoracic or abdominal movements were present 
and central when these movements were absent. An experienced teclinician scored all the 
events manually. Patients were classified to have significant upper airway collapsibility 
when the apnoea-hypopnoea index or respiratory disturbance index (RDI) was >15 
events/hour. Nocturnal hypoxaemia of SpOz < 90% lasting > 30% of the night is 
normally considered for long-term oxygen therapy in chionic lung diseases (188). ACC? 
guidelines in 1999 (189) suggested considering NIV in symptomatic nemomuscular 
disease patients nocturnal desaturation of > 88% lasted 5 min or longer. There is 
considerable variation in recommendations regarding significant nocturnal desaturation.
Overnight oximetry: Nocturnal pulse oximetiy was carried out at home using Minolta 
pulsox (Sampling frequency: one in every 5 sec) 3i model (fig 3.2.2.1). Patients were 
encouraged to use it for at least 5-6 hours on the day of the study. Mean overnight 
oxygen saturation and time spent below SpOz of 90% were recorded. Desaturation index 
(DI) was taken to be significant when episodes of 4% or greater SpCE drop lasted 10 sec
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and the frequency was >15 events/hour. 7 MyD and 10 MND subjects were assessed 
with nocturnal pulse oximetry.
Fig 3.2.2.1 : Minolta pulse oximeter.
SRBD definition for the purpose of the study:
SRBD consisted of upper airway collapsibility (RDI/DI > 15events/hr), persistently low 
baseline SpOz (< 90%), lasting for greater than 10 min. at a stretch, REM state 
hypoventilation and/or daytime hypercapnia.
3.2.3 Results
Prevalence of excessive daytime sleepiness as assessed by Epworth sleepiness scale (ESS 
> 11) was highest in MyD patients (37%). The main symptoms for referral included 
tiredness and excessive sleepiness in MyD (67%), breathlessness in MND (76%). 
Sixteen patients (43.2%) assessed had significant sleep disordered breathing. Symptoms 
of apnoeas, snoring and disturbed sleep were more prevalent in the SRBD group. 
However orthopnoea and breathlessness was not a feature even in patients with daytime 
hypercapnia.
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Myotonie Dystrophy subgroup:
Table 3.2.3.1: Baseline patient characteristics. Patients with SRBD tended to be older 
and had higher BMI in comparison to non-SRBD group, though this was not statistically 
significant.
SRBD group 
(n=9)
Non-SRBD group
(ii=16)
Age (years) 43.1 (35.7-50.5) 38.8 (33.3-44.2)
BMI (kg/m )^ 28.4 (23.8-33.0) 24.6 (20.0-29.2)
ESS 10.6 (6.7-14.4) 12.3 (9.3-15.2)
Table 3.2.3.2: Summary of the daytime lung function tests and noctur 
MyD.
SRBD group 
(11=9)
Normal overnight 
study group (n=16)
% Predicted FEV, 68.0 (44.4-91.6) 74.3 (65.3-83.3)
% Predicted F VC 71.5 (49.4-93.6) 79.1 (70.6-87.7)
% fall in supine F VC 11.4 (4.5-18.3) 7.8(4.2-11.5)
RDEDI (events/hour) 22.8 (8.8-36.8) 2.7 (0.4-5.0)*
Time spent < 90% (min) 79.9(50.1-109.7) 6.2(1.8-10.7)*
Mean overnight SpOz 90.6 (89.9-91.3) 93.8 (92.5-95.0)*
*p < 0.05 and significantly different in comparison to SRBD group.
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Fig 3.2.3.1: G raph  sh o w in g  the n o n -in v as iv e  re sp ira to ry  m u sc le  s tren g th  (E rro r bars 
re flec t the 95%  C l)  in the  tw o d iffe ren t g roups. A s w ith  the  p e rcen t-p red ic ted  FV C  there  
w as ten d en cy  to  have low er m o u th  p re ssu res  in  S R B D  group . B u t the  d iffe rences 
b e tw een  the tw o g roups w ere  no t s ta tis tica lly  sign ifican t.
C o rre la tio n  b e tw een  FV C  and  m o u th  p re ssu re s  w as w eak  (r  =  0 .4  w ith  M IP , p= 0 .0 8 , r =
0.5 w ith  S N IP  and  r =  0 .6  w ith  M E P, p = 0 .1 8 ). H o w ev er fo r the  w ho le  g roup  FV C 
co rre la ted  w ell w ith  arteria l pC O ] (r= -0 .7 , p < 0 .0 5 ). It w as o f  in terest to no te  that th ree 
sub jec ts  (ou t o f  n ine) w ith  S R B D  had  n o rm al p red ic ted  FV C  and  th ree  p a tien ts  (ou t o f  
16) had  <  60%  p red ic ted  FV C  and  d id  no t h av e  SR B D . T hus the p o sitiv e  p red ic tiv e  
value  o f  FV C  <  60%  fo r p red ic tin g  u n d erly in g  S R B D  (sen sitiv ity ) w o u ld  be 67%  and 
sp ec ific ity  (FV C  >  60%  ex c lu d in g  S R B D ) w o u ld  be 85% . C orre la tion  b e tw een  FV C  and 
RD I w as a lso  w eak  at 0.3 (p= 0 .16 ). Inc idence  o f  u p p e r a irw ay  co llap s ib ility  w as h ig h er 
in p a tien ts  w ith  low  m ean  o v ern ig h t o x y g en  sa tu ra tion . D ay tim e PaC O z w as h igher in 
S R B D  pa tien ts  [m ean 6.3 (0 .9 ) kP a vs 5.8 (0 .3 ) k P a  in non  SR B D ] tho u g h  th is d id  not 
reach  sta tis tica l sign ificance .
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Table 3.2.3,3: Sleep stages in Myotonie Dystrophy in 18 subjects who underwent PSG.
Statistically there were no significant differences between the various sleep stages within 
the two groups.
Patients with SRBD 
(n = 8)
Patients without SRBD 
(n = 10)
TST (min) 285.1 (219.3-350.9) 322.3(290.6-353.9)
SE (%) 79.0 (67.8-90.1) 73.7(69.5-77.9)
% Stage I 24.1(14.0-34.2) 26.7(18.1-35.4)
% Stage II 40.7(30.7-50.8) 34.3(29.0-39.6)
% Stage III 9.8(5.8-13.9) 20.2(11.7-28.7)
% Stage IV 3.1(0.3-5.9) 3.9(2.0-5.7)
% REM 15.0(7.3-22.7) 9.0(0.4-11.6)
There was predominance of lighter stages of sleep in comparison to slow wave sleep in 
myotonic dystrophy patients. In 3 out of the 7 patients with compromised nocturnal 
oxygenation, this could not be predicted from any of the daytime tests. ESS was normal 
in two of these patients and the patient with sleep apnoea had only mildly elevated ESS at 
12. FVC was normal in all the three patients though MEP was reduced more than MIP, 
which is known to occur in MyD. The common sleep abnormalities noted in these 
patients included central sleep apnoea (1 patient) and nocturnal hypoventilation (2 
patients). A sleep tracing of a patient showing REM hypoventilation is shown in fig 
3.2.3.2.
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Fig 3.2.3.2: REM hypoventilation.
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MND subgroup:
Table 3.2.3.4: Baseline Characteristics. Results in mean (95% Cl).
SRBD group 
(n=7)
Non-SRBD group 
(11=5)
Age (years) 64.1(55.4-72.9) 52.2(35.2-69.2)
BMI (kg/m )^ 25.3(21.4-29.2) 28.1(26.0-30.2)
ESS 5.0(3.4-6.6) 4.2(3.8-46)
Table 3.2.3.5: Differences between the two subgroups.
SRBD group 
(n=7)
Normal overnight 
study group (n=5)
% Predicted FEV i 67.3(49.4-85.2) 75.3 (37.6-113.0)
% Predicted FVC 67.2 (45.9-88.6) 72.7(47.2-98.1)
% fall in supine VC 17.6 (0.5-34.7) 4.0 (-1.0-9.0)*
RDEDI (events/hour) 2.0(1.1-5.0) 0.6 (0-2.0)
Time spent < 90% (min) 39.7(6.0-73.3) 6.2(46-9.1)*
Mean overnight SpOz 90.8(89.5-92.2) 95.6(94.6-96.6)*
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*p<0.05
Fig 3.2.3.3: Mouth pressure difference between SRBD and non-SRBD group. Though 
MIP and MEP showed downward trend in SRBD group, SNIP was significantly different.
In most patients with motor neurone disease, overnight monitoring did not reveal any 
additional information that could not be predicted from their symptoms, daytime lung 
function assessment and blood gas analysis. In the two patients who had PSG, this was 
useful only to identify sleep macro architecture. Correlation between mouth pressures and 
FVC was weak (MIP vs FVC r=0.6, p=0.2, MEP vs FVC r=0.4, p=0.08, SNIP vs FVC 
r=0.6, p=0.2). The correlation between percent predicted FVC and RDI was also weak 
(r—0.2, p=0.15). There was significant correlation between FVC and PaCOz at r=0.8, 
p=0.03.
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3.2.4 Discussion
111 neuromuscular diseases it is sometimes difficult to determine how much the nocturnal 
events contribute to daytime symptoms. Though noctui'nal events precede daytime 
symptoms and blood gas abnormality, their occurrence can be difficult to predict from 
daytime measurements. Often in neuromuscular diseases, symptoms of respiratory 
muscle weakness can be delayed due to reduced mobility and the associated peripheral 
muscle weakness may in fact mask any concomitant respiratory symptoms. Facial 
muscle weakness can also underestimate mouth pressures and hence when reduced their 
interpretation becomes difficult. Daytime hypercapnia is a late event. In presence of 
symptoms and normal blood gases, therefore, often sleep studies are resorted to. To date 
there is no conclusive evidence of benefit with routine monitoring. This study adds data 
to the existing evidence. However it also identifies a group of myotonic dystrophy 
patients with significant nocturnal disturbance, albeit small (12% of myotonic dystrophy 
patients) that will be missed if only mouth pressures, spirometry and arterial blood gases 
are employed for assessment. Generally it is known that patients with neuromuscular 
diseases mn into complications when FVC < 40-50% of the predicted (190). Hence, 3 
patients with myotonic dystrophy in oin patient population with normal FVC and 
significant SRBD merit further discussion. This may well be related to the differences in 
muscle groups affected. Since diapluagm function was not specifically measured in this 
group, it will be interesting to see in further studies if such a scenario is due to 
predominantly affected diapliragm with sparing of the other respiratory muscles. Does it 
really matter if we do not identify these patients as it is well known that compliance with 
NIV in MyD patients is not as good as in other neuromuscular diseases? (109). It is
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debatable, as the experience with NIV in MyD is still in its infancy. Myotonic dystrophy 
patients are known to have neuropsychiatrie and cognitive impairment and it will also be 
interesting to see if this solely contributes to the non-compliance. Since more of these
patients are likely to be assessed for NIV in the future it is worth trying to identify the 
subgroup of patients who will benefit from it. There is emerging evidence that NIV does 
improve daytime blood gases in MyD patients (109).
A critique of our methodology is that there was no clear distinction between patients who 
underwent in-hospital sleep studies and those in their own homes. This was entirely 
dependent on patient preference, taking into account the distance to travel, mobility and 
willingness. Unattended studies are likely to underestimate the occurrence of respiratory 
events especially in the presence of respiratory muscle weakness and it is also well 
known that obstmctive events can be underscored as central events when using non- 
invasive respiratory movement analysis techniques (191,192). Those who were admitted 
for polysomnography were assessed on a single night and the lower percentage of slow 
wave sleep obsei’ved could well be attributed to the ‘first-night’ effect.
We acknowledge that DI and RDI are not directly comparable and that our chosen index 
of > 15 events/hour is a high threshold for SRBD in general. However, since sleep 
breathing therapies are usually instituted when SRBD is marked (109) and the sampling 
rate of the pulse oximeter used would have high specificity at this level to pick up 
desaturations (148), we opted to use this threshold value for RDI/DI. These factors could 
have contributed to a smaller proportion of SRBD patients being identified in our group.
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Nocturnal pulse oximetry has recently been shown to be useful to detect early 
desaturations during overnight monitoring in motor neurone disease (193). This study 
adds further evidence that home monitoring with overnight oximetry may be a useful tool 
in selected group of patients with neuromuscular diseases. It is well known that REM 
hypoventilation precedes more prolonged desaturations during the night and total reliance 
on overnight oximetry is likely to miss this group of patients. Eight out of seventeen 
patients (47%) in the pulse oximetry group had home study. It was technically feasible in 
all of them and patients did not report any problems with its use. Simplicity of the 
technique makes it an attractive option especially for some cluonic neuromuscular 
diseases where patients are reluctant to come into hospital. The data available on 
Duchenne muscular dystrophy in this regard can also be applied to other neuromuscular 
diseases (194).
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3.2.5 Conclusions
Prevalence of SRBD was 43.2% in symptomatic individuals referred for assessment in 
our clinic. Common symptoms of presentation included excessive sleepiness and 
tiredness in MyD and breathlessness in MND. Correlatioon between daytime 
measurements (FVC, MIP, SNIP, MEP) and nocturnal events (RDI/DI) was poor. It was 
feasible to carry out nocturnal oximetry in both MyD and MND patients with 36.8% of 
studies detecting significant SRBD (vs 50% detected on the PSG).
Routine sleep studies did not add any further value in comparison to daytime 
measurements apart from 3 patients (12% MyD) who would be missed if only daytime 
studies were relied on. Of all the non-invasive tests, FVC correlates best with daytime 
hypercapnia. Detailed sleep studies seem best utilised as targeted investigation in 
patients with multiple symptoms that raise suspicion of nocturnal hypoventilation and/or 
upper airway collapsibility with normal awake arterial blood gases. Certainly it was 
commoner in older and heavier individuals though statistical significance was not 
reached in our study.
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3.3 Respiratory Muscle Strength in Myotonic Dystrophy (MyD)
With this background we went on to:
1) Review retrospectively all the MyD patients that had attended our respiratory units.
2) Evaluate the volitional and nonvolitional respiratory muscle strength in patients with 
MyD.
3.3.1 Five-year case note review
As a preamble to my studies, we undertook retrospective case note review of all the 40 
myotonic dystrophy patients that could be traced who attended the two Respiratory units 
at Gartnavel General Hospital and Glasgow Royal Infirmary over the last 5 years. Time 
to clinic referral from the onset of respiratory symptoms was variable (0-72 months). 
Twenty-one patients required ventilatory support for symptomatic respiratory failure, 
nocturnal hypoventilation or upper airway collapsibility. Fifteen received bilevel pressure 
support and six continuous positive airway support.
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Table 3.3.1.1: Differences between patients that required NIV and those who didn’t.
Patients requiring NIV Not requiring NIV
Patient number 21 19
Age, years 42.0(14.1) 40.4(12.1)
Epworth Sleepiness Scale at presentation 13.4(3.9) 12.3(6.4)
Body Mass Index (BMI) kg/m^ 33.7(8.7) 24.8(4.3)*
% predicted FEVl 63.9(22.7) 74.0(15.0)
% predicted FVC 65.8(25.0) 79.9(16.2)
MIP (cmHzO) 37.4(19.3) 41.4(15.7)
MEP (cmHzO) 34.1(14.6) 40.3(14.5)
Obshuctive Sleep Apnoea (RDI > 15/hr) 
(patient number)
Mean overnight oxygen saturation (%)
14
90.6(4.4)
2
93.7(3.1)*
Results in mean (SD). * p<0.05
With this review, it was apparent that Myotonic Dystrophy patient who later required 
NIV had lower FVC and maximal expiratory/inspiratory pressures at presentation but this 
did not reach statistical significance. The mouth pressures in both the groups were lower 
than predicted normal and hence difficult to conceptualise the level at which this 
compromised ventilation the most. Interestingly, those who went on to require NIV had a 
significantly higher BMI. Compliance with NIV was universally poor.
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3.3.2 Hypotheses:
1. Volitional tests underestimate respiratory muscle strength in MyD.
2. Nonvolitional tests would be better at identifying patients with significant SRBD.
3. There would be a correlation between respiratory muscle strength assessed by BAMPS 
and peripheral muscle strength,
3.3.3 Study Design
A group of 10 normal subjects and 10 patients with MyD took part in this study. Study 
measurements were carried out on two occasions 4-6 months apart in the Respiratory 
Muscle Laboratory at Gartnavel General Hospital.
Visit 1:
1. Obtain written informed consent.
2. Eligibility check with particular attention to symptoms and mode of confirmation of 
underlying diagnosis.
3. All subjects were examined to categorise their muscular impairment scale (195, 
Appendix V).
Grade 0: No muscular impairment 
Grade 1 : Minimal signs 
Grade 2: Distal weakness 
Grade 3: Mild Proximal weakness 
Grade 4: Severe proximal weakness
Muscular disability rating scale (MDRS) is a five-point rating scale, based on manual 
testing of 11 muscle groups and has been validated in many studies. It is thought to be
1 2 0
helpful in establishing the natural history of the disease and to define groups of patients 
with similar level of disability.
4. Complete the following questiomiaires:
Epworth Sleepiness Scale Score (ESS) -  to assess daytime sleepiness (Appendix III, 
179).
The ESS is a widely used eight-item questioimaire that measures the subjective sensation 
of recent sleepiness. Subjects are asked to rate how likely they are to fall asleep, as 
opposed to just feeling tired, in eight specific quiet or relaxed situations. The scale runs 
from zero (unlikely to fall asleep in any of the eight relaxed situations) to 24 (high chance 
of falling asleep in all eight situations).
The Short Form 36 Health Survey Questionnaire (SF 36) -  as a measure of general 
well being and functioning (196, Appendix IV).
The SF-36 is a widely used and validated questionnaire that measures QoL in health- 
related states and conditions. This instiument does not contain questions related directly 
to the effects of sleep disorders but instead has questions that focus on QoL in general 
rather than in relation to any specific disease. The SF-36 produces a profile of eight 
dimensions of health status -
(i) limitations in physical activities because of health problems
(ii) limitations in social activities because of physical health problems
(iii) limitations in usual role activities because of physical health problems
(iv) bodily pain
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(v) general mental health
(vi) limitations in usual role activities because of emotional problems
(vii) vitality
(viii) general health perceptions
However two summary scores can be extrapolated from these 8 dimensions: a physical 
and a mental component summary. The SF-36 has been used in many studies involving 
different medical conditions and hence was used in my study. The question scores on 
each variable can be summed and transformed to a scale from 0 to 100 (from worst health 
to best health apart from the pain score which is the reverse) (197).
Hospital Anxiety and Depression Score (HAD) (198, Appendix VI) -  to assess 
psychological aspects.
This questionnaire analysed the severity of underlying anxiety and depression. The 
questionnaire contains seven items reflecting anxiety and seven reflecting depression. (Of 
the seven depression items five reflect aspects of reduction in pleasure response). Each 
item was answered by the patient on a four point (0-3) response category so the possible 
scores ranged from 0 to 21 for anxiety and 0 to 21 for depression. A score of 0 to 7 for 
either subscale was regarded as being in the noimal range; a score of 11 or higher 
indicated presence of the mood disorder and a score of 8 to 10 being just suggestive of 
the presence of the respective state.
5. Baseline pulmonary function test -  to include Forced Expiratory Volume in 1 sec and 
Forced Vital Capacity
6. Lying and standing vital capacity
7. Oxygen Saturation Assessment
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8. Arterial Blood Gases if SpOz < 92% or awake arterial blood gases in all patients who 
underwent in-patient polysomnography.
9. Respiratory Muscle Strength was assessed using volitional tests such as MIP, MEP, 
SNIP and sniff transdiaphragmatic pressure after placement of oesophageal and gastric 
balloon catheters. MIP < 80cm HzO, MEP < 90cm HzO and SNIP < 70cm HzO were 
considered to be significantly reduced. Peak MIP and MEP were also recorded as there 
are studies which have shown that they may be easier to obtain and equally reliable in 
subjects (199). Non-volitional respiratory muscle strength was measured using bilateral 
anterior magnetic phrenic nerve stimulation technique to obtain twitch 
transdiaphragmatic pressure.
10. Peripheral muscle strength was assessed by maximal voluntary contraction of the 
quadriceps muscle. Quadriceps strength was measured in the dominant leg.
11. Dynamic Compliance of the respiratory system was calculated during a period of 
quiet breathing through a heated pneumotachograph as the ratio of difference in tidal 
volume to change in the oesophageal pressure.
12. Patients were booked in for either overnight oximetry or full polysomnography if not
done before or subjects had symptoms of excessive daytime sleepiness, sleep
disturbances or ESS over 11.
- to obtain information on sleep quality by analysing time spent in different 
stages of sleep as defined by electro encéphalographie (EEG) criteria 
to assess episodes of desaturation defined as a drop in SpOz by 4% 
to exclude associated sleep apnoea hypopnoea syndrome
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Visit 2: 4-6 months later subjects were reassessed with:
1. Review of Symptoms
2. Questionnaires
3. Pulmonary Function Tests, Lying and Standing VC
4. Oxygen saturation ± arterial blood gas assessment
5. Respiratory muscle strength assessment -  volitional and nonvolitional
6. Assessment of peripheral muscle strength
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3.3.4: Results
10 normal subjects (6 men, 4 women) and 10 patients with myotonic dystrophy (6 men, 4 
women) took part in this study. 6 patients had no physical disability as assessed by 
MDRS, 2 had minimal signs, 1 with distal weakness and 1 other with mild proximal 
weakness. They were all ambulatory. Demographics are summarised in table 3.3.4.1.
Table 3.3.4.1: Demographic details.
Normal subjects n = 10 MyD patients n = 10
(6M:4F) (6M:4F)
Age (years) 30.1(5.2) 37.2(9.8)
Body mass index (kg/m2) 24.3(3.1) 27.5(5.4)
Epworth sleepiness scale 5.8(3.4) 16.1(4.0)*
Results in mean (SD). * p<0.05 
Symptom Evaluation:
The common symptoms patients with myotonic dystrophy presented included tiredness 
(90%), excessive sleepiness (70%) and disturbed sleep mostly due to snoring (40%). 
Considering Epworth sleepiness scale score > 11 as significant 90% of the patients 
studied were hypersomnolent during the daytime.
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Questionnaires:
The SF-36 results are summarised in Tables 3.3.4.2. 
Table 3.3.4.2: SF-36 scores in normal and MyD subjects.
Normal subjects n = 10 MyD subjects n = 10
Physical Functioning 93.9(13.2) 52.5 (25.2)*
Role-Physical 94.4(16.7) 90.6(26.5)
Role-Mental 92.6(22.2) 87.5(24.8)
Social Functioning 80.2(15.5) 52.8(16.5)*
Mental Health 84.4(9.0) 64.0(12.1)*
Energy 78.9(13.6) 40.0(10.0)*
Pain 92.6(9.6) 59.7(20.9)*
Health Perception 73.3(12.5) 43.8(10.9)*
Results presented as mean (SD), * = p < 0.05.
Compared to normal subjects, MyD patients had lower scores in all the components of 
SF-36. However it was interesting to note that role limitations due to physical and 
emotional problem scores though lower in MyD patients did not reach statistical 
significance in comparison to normal subjects. When subgroups of MyD patients were 
looked at, statistically there were no differences in any of the 8  components of SF-36
between patients with normal nocturnal parameters and those with significant respiratory 
disturbance during the night (table 3.4.4.3).
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Table 3.3.4.3: SF-36 scores in subgroups of MyD patients.
MyD subjects with normal 
nocturnal parameters n = 6
MyD subjects 
nocturnal desaturators n = 4
Physical Functioning 62.0(22.5) 36.7(24.7)
Role-Physical 1 0 0 .0 (0 .0 ) 75.0(43.3)
Role-Mental 86.7(29.8) 88.9(19.2)
Social Functioning 57.8(18.3) 44.4(11.1)
Mental Health 62.4(15.1) 66.7(6.1)
Energy 39.0(12.9) 41.7(2.9)
Pain 66.7(20.8) 48.1(17.0)
Health Perception 49.0(8.2) 35.0(10.0)
On the HAD scale, MyD patients had significantly higher scores compared to normal 
individuals with the mean anxiety score of 7.9(4.5) (vs 3.3(1.6 ) in normals} and mean 
depression score of 10.4(4.6) {vs 3.2(1.7) in controls).
Pulmonary Function Tests:
Looking at basic spirometry (fig 3.3.4.1), there was no significant difference between the 
predicted FEVi and FVC for the whole group between the normal subjects and patients 
with myotonic dystrophy though there was tendency in the MyD group to have lower 
values.
127
160
120
"S 80
40
□  Normal 
■  MyD
FEVI FVC
Fig 3.3.4.1: Baseline spirometry between the normal subjects and patients with myotonic 
dystrophy. Error bars reflect SD for the group.
However looking at the mouth pressures (fig 3.3.4.2), both inspiratory and expiratory 
pressures were markedly reduced in MyD group. MEP tended to be more reduced than 
MIP. Correlation between FVC and MIP, MEP was good in the MyD group [fig 3.3.4.3 
and fig 3.3.4.4 (r=0.7, p=0.02)]. Within the normal subjects, however, the correlation 
between mouth pressures and FVC was not significant.
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Fig 3.3.4.2: Mouth pressure differences between normal subjects and patients with MyD.
MIP vs % Fred FVC
1 2 0 “
OT
EÜc
E 40 “
0 -
0 40 80 120
O  SRBD 
•  Non-SRBD
^  Normal subjects
% Pred FVC
Fig 3.3.4.3: Correlation between FVC and MIP in MyD (r-0.7, p=0.022). This graph 
also highlights an interesting patient who has normal FVC and reasonably preserved MIP 
who has significant SRBD (arrow).
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Fig 3.3.4.4: Correlation between FVC and MEP in MyD (t-0.7, p-0.021).
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Fig 3.3.4.5: Correlation between FVC and SNIP for the whole group (i-0.5, p=0.02).
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Table 3.3.4.4: Invasive respiratory muscle strength between normal subjects and MyD 
patients.
Normal n = 10 MyD n = 10
Sniff Poes (cm H2O) 80.5 (9.1) 57.3 (26.3)*
Sniff Pdi (cm H2O) 89.5 (24.2) 67.1(30.7)
Right TwPdi (cm H2O) 11.2 (2.9) 5.4 (1.8)
Left TwPdi (cm H2O) 12.6 (3.3) 8 .1(3.6)
TwPdi (cm H2O) 25.0 (6.4) 17.1(9.4)
Cough Pgas (cm H2O) 140.6 (43.4) 105.3 (41.7)
Dynamic compliance 
(L.cmHjO-')
0.19(0.10) 0.11 (0.06)*
* p < 0.05
In comparison to normal subjects, MyD patients had generally lower transdiaphragmatic 
and cough gastric pressures. However in the group we studied only the sniff Poes and 
the dynamic compliance was significantly lower in MyD patients. Hence we looked at 
how patients with significant nocturnal disturbances matched with those who had normal 
sleep pattern and overnight oxygen saturation (table 3.3.4.5, fig 3.3.4.3).
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Table 3.3,4.5: Differences between patients with significant nocturnal respiratory 
disturbance and those with normal overnight oxygen saturation.
Patients with SRBD 
n = 4(3M :lF)
Patients without SRBD 
n = 6 (3M:3F)
p value
Age (years) 40.2(8.4) 35.2(10.9) 0.45
Body mass index (kg/m^) 32.8(2.3) 24.8(4.1)* 0 . 0 2
Epworth sleepiness scale 15.5(2.4) 16.6(5.2) 1 . 0 0
* p < 0.05
Patients with significant SRBD (mean oxygen saturation < 90%, upper airway 
collapsibility defined as apnoea hypopnoea index > 15 events/hour, REM hypoventilation 
and/or awake hypercapnia) were older though not significantly. Excessive daytime 
sleepiness was a feature of MyD patients even in absence of significant nocturnal 
respiratory disturbance. Body mass index was significantly higher in patients with 
nocturnal desaturation. However the correlation between BMI and RDI/DI was weak 
(1- - 0 . 1).
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Fig 3.3.4 7: Differences in mouth pressures between the MyD subgroups.
There was tendency of SNIP, MEP and peak MEP to be lower in patients who had 
significant nocturnal desaturation. However these were not statistically significant 
between the subgroups.
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Table 3,3.4.6: Invasive respiratory muscle strength between the subgroups.
Patients with SRBD n = 4 Patients with normal 
overnight oxygen n = 6
Sniff Poes (cm H2O) 48.1(29.6) 63.5(24.6)
Sniff Pdi (cmH 2 0 ) 50.0(35.4) 78.6(23.5)
Right TwPdi (cm H2O) 3.6(0.6 ) 6.4(1.3)*
Left TwPdi (cm H2O) 4.8(2.7) 10.1(2.4)^
Bilateral TwPdi (cm H2O) 8.7(6.2) 22.6(6.6)*
Cough Pgas (cm H2O) 100.0(46.2) 108.8(42.5)
Dynamic compliance 
(LxmHzO')
0.08(0.02) 0.13(0.07)
* p < 0.05; ' =0.07
There was tendency in MyD patients who had nocturnal disturbances to have lower sniff 
Poes and Pdi values though statistically this wasn’t significant. However bilateral TwPdi 
was a good des eliminator of the two subgroups. Paralysed diapluagm as seen on 
oesophageal and gastric pressure tracings of one of the patients with low Pdi is shown in 
fig3.3.4.7.
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Pdi = Pagas-Poes= 1cm H20
Pgas = “6  cm H2O
Poes = -  5cm H2O
Fig 3.3.4.S: Diaphragm paralysis as evident on oesophageal and gastric pressure tracing 
(GainX5).
Conelation between volitional and non volitional tests are now explored.
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Fig 3.3.4.9: Correlation of sniff Pdi and FVC (i-0.45, p=0.04).
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Fig 3.3.4.10: Relation between FVC and TwPdi (i-0.5, p=0.01).
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Fig 3.3.4.11: Relation between MIP and TwPdi (r=0.5, p=0.02 for the whole group).
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Fig 3.3.4.12: Relation between TwPdi and MEP (i-0.58, p=0.007).
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Fig 3.3.4.13: Relation between Sniff and Tw Pdi. This clearly demonstrates the 
superiority of Tw Pdi results in assessing diaphragm strength. Solid lines stand for 
89.5cm H2O for sniff Pdi (recorded mean value for normal subjects) and 20 cm H2O on 
bilateral Tw Pdi. There were subjects who would be classified to have weak diapliragms 
on sniff Pdi who had normal Tw Pdi. The reasons for slightly lower than expected sniff 
Pdi for the group are explored in the discussion.
3 normal subjects and all the MyD subjects had MIP < 80cm H2O. 4 normal and 7 MyD 
subjects had lower than the expected sniff Pdi. All the normal subjects had TwPdi > 18 
cm H2O and 3 MyD subjects had low TwPdi. Only considering sniff Pdi, 55% of the 
group would have been thought to have low diapliragm strength. However, only 15% of 
the group actually had reduced strength as assessed by Tw Pdi.
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Fig 3.3.4.14: Correlation between MEP and Cough Pgas (r=0.5).
Though the strength of correlation was strong between invasive and non invasive tests for 
the whole group, they were not significant to differentiate SRBD and non SRBD group.
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Sleep and arterial blood gas analysis:
Only the MyD patients had overnight monitoring. Three patients did not wish to come 
into the hospital and hence home overnight oximetry was carried out on them using 
Minolta pulse oximeter. They were specifically asked to make a note of the time they 
went to bed, awakening time and also about the subjective quality of sleep on the study 
night. The rest of the patients (n=7) underwent full polysomnography in hospital. All the 
three subjects who had overnight oximetry had a mean oxygen saturation of 96% on air.
It was interesting to note that all these 3 subjects had TwPdi within the normal range. 
The polysomnographic data are summarised in table 3.3.4.7.
Table 3.3.4.7: Polysomnography in Myotonic Dystrophy patients (n-7).
Mean (SD)
TST (min) 295.1 (121.3)
SE (%) 79.0 (14.6)
Stage I (%) 25.1 (14.0)
Stage II (%) 35.7 (20.8)
Stage III (%) 15.8 (6.7)
Stage IV (%) 7.1 (8.2)
REM (%) 15.0(12.7)
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Generally lighter stages of sleep (stages I, II) were noted to be higher than in the normal 
range though we did not control for the first-night effect. This was irrespective of 
whether the patients had significant nocturnal desaturation or upper airway collapsibility 
that could account for the disrupted sleep architecture.
Four out of the 10 subjects had significant upper airway collapsibility or evidence of 
hypoventilation. Two of them had obstmctive sleep apnoea with nocturnal desaturation 
[(mean SpCE < 90% on air(tracing shown in fig 3.3.4.15)], one had central sleep apnoea 
[31 events/hour (fig 3.3.4.16)] and the other had severe nocturnal hypoventilation with 
mean SpOz = 87% and raised awake CO2 levels.
1001
Fig 3.4.4.15: Shows nocturnal hypoventilation with initial SpO] in low 90s and as the 
night progresses there is progressive drift in the baseline with associated brief 
desaturations associated with increased heart rate (not shown) suggesting underlying 
sleep apnoea.
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Fig 3.3.4.16: Polysomnographic data in a patient with central sleep apnoea.
Arterial blood gas analysis revealed mean Pa0 2  of 10.2(2.1) and PaC0 2  of 6.3(0.9) for 
the MyD group. As could be expected, the correlation between PaC0 2  and HCO3 was 
significant (1-O.6 , p=0.04). The correlation between PaC0 2  levels and bilateral TwPdi 
was also good at 1- - 0 .7 , p~0.04 (fig 3.4.4.17) as was that with FVC (r—0.7, p=^0.03).
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Fig 3.3.4.17: Correlation between PaC0 2  and Tw Pdi.
One patient with central sleep apnoea had normal FVC, minimally reduced mouth 
pressures and normal sniff Pdi (98.9 cm H2 O). His bilateral TwPdi was minimally 
reduced at 17.6cm H2O. This patient highlights the complex interaction between various 
factors that result in ventilatory failure in MyD (fig 1.8.1.1).
When considered in combination on a linear regression model, hypercapnia was 
significantly predicted by FVC and Tw Pdi (p=0.019) but not by Sniff Pdi or the mouth 
pressures.
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Peripheral Muscle Strength:
Maximal voluntary contraction of quadriceps was 40.9 (9.9)kg in normal subjects and 
32.8 (13.8)kg in MyD subjects. In patients with nocturnal disturbance MVC was lower at 
30.4(11.4) in comparison to 34.4(16.0) in patients who had normal nocturnal oxygen 
levels. However this trend was not statistically significant. The correlation between 
general muscle weakness as assessed with MDRS and MVC quadriceps was only weak 
(1--0.3, p=0.3).
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Fig 3.3.4.18: Relation between peripheral muscle strength as assessed by MVC 
quadriceps and nonvolitional diaphragm strength (t-0.4, p=0.4). There was no 
significant coirelation in the variables either in normal individuals or in MyD subjects.
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Analysis of repeat tests in 4-6 months:
Only 9 nomial controls and 7 in the MyD group attended for the repeat studies. There 
was no change in the MDRS scoring of any of the MyD subjects. Again the SF-36 scores 
were reduced in most of the domains compared to the normal subjects and HAD scores 
were higher suggestive of increased prevalence of mood disorders.
Table 3.3.4.8: Summarises the non-invasive pulmonary function tests in the normal and 
MyD subjects. Results given as mean (SD).
Normal subjects 
I visit 11 = 10
Normal subjects 
II visit n = 9
MyD subjects 
I visit n = 10
MyD subjects 
II visit n = 7
%Pred FEVi 103.7(6.5) 98.1(12.5) 77.4(25.5) 72.5(24.4)
% Pred FVC 105.9(12.4) 101.4(15.5) 83.4(28.3) 76,3(24.7)
% fall in supine VC 3.9(3.2) 2.4(2.4) 10.5(7.0) 15.2(13.3)
MIP in cm H2O 89.4(22.1) 86.2(19.9) 42.5(20.4) 31.9(10.1)
Peak MIP-cm H2O 114.2(24.2) 107.4(23.0) 57.2(26.1) 35.4(19.1)
SNIP in cm H2O 98.5(25.1) 83.7(20.4) 41.9(21.7) 37.2(18.4)
MEP in cm H2O 99.7(24.5) 98.1(20.5) 40.1(16.7) 46.9(17.4)
Peak MEP-cm H2O 129.8(22.9) 126.0(24.6) 54.0(21.6) 51.6(20.5)
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It appeared that there was significant decline in maximal inspiratory pressure in MyD 
patients dining the second visit in association with fall in supine vital capacity. On 
reflection, this may well be related to the development of significant diaphragm weakness
in the group that was studied. However analysing data for the 7 subjects from the initial 
visit, MIP was similar to the mean value obtained at the second visit [30.4(10.2) cm H2O 
at the initial visit]. Fig 3.3.4.19, 3.3.4.20 summarise the volitional and non-volitional 
tests between the two visits.
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Fig 3.3.4.19; Volitioanl and Non-volitional respiratory muscle parameters in normal 
subjects. The slight increment noted in sniff Poes, sniff Pdi and cough Pgas could well be 
a learning effect and there was no significant difference compared to the I visit.
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Fig 3.3.4.20: Volitional and Non-volitional respiratory muscle parameters between the 
two visits in MyD.
There was no statistical difference between the 2 visits in sniff or Tw Pdi and cough Pgas 
in either normal or MyD subjects. MVC quadriceps was also similar on the two 
occasions tested being 28.3(14.1)kg on the initial visit and 24.5(10.l)kg on the second 
visit in the 7 MyD subjects studied. Since the disease progression in patients with MyD 
is long, stability of the respiratory muscle strength assessment both by volitional and non- 
volitional tests in that period is quite reassuring.
Four subjects with sleep apnoea and/or hypoventilation were initiated on NIV. At II visit 
mean use of bilevel positive airway pressure ventilation (BIPAP) was only 2.4 
hours/night and one patient had discontinued its use completely as he had no significant
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symptomatic improvement. It was interesting to note that one patient with 
hypoventilation and daytime hypercapnia, who used NIV on a regular basis (Mean of 
3.5hours use/night) had no change in her Tw Pdi on repeat testing (Tw Pdi of 8 cm H2O 
on both occasions).
3.3.5: Discussion
It appeared that most patients with MyD attributed their longstanding tiredness and 
sleepiness to their underlying myotonic dystrophy and none were aware that respiratory 
impairment could be a contributing factor for their symptoms. There is increasing effort 
from the medical profession to raise awareness of the various complications that can 
occur in MyD. Myotonic Dystrophy care card illustrates one such attempt (appendix 
VII). However treatment of respiratory complications has remained a challenge. The 
associated neuropsychiatrie disturbances may make compliance with any kind of 
treatment difficult which especially applies to non-invasive ventilation. Many of the 
patients were particularly reluctant to attend clinics in the mornings and this may well be 
something to bear in mind while formulating care plans for these patients.
Assessment of QoL
MyD patients scored lower in most of the domains of SF-36 compared to normal and this 
stresses the implications the disease has on QoL. Though scores >11 are considered to be 
clinically relevant for the diagnosis of anxiety or depression on HAD scale, mean scores 
were less than this. However half the MyD group fulfilled the criteria for depression with
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HAD score > 11. This was equally common in both subjects with SRBD and those 
without. There was no direct correlation of SF 36 or HAD scores with FVC, mouth 
pressures or PaCOi. MyD patients with or without SRBD are significantly sleepy as 
assessed by ESS.
Volitional and non volitional respiratory muscle strength and their relevance to 
SRBD
We found bilateral anterior magnetic phrenic nerve stimulation technique to be a useful 
method to assess non-volitional respiratory muscle strength in patients with MyD. To our 
knowledge, this is the first time BAMPS has been tested this way in MyD. Patients 
tolerated the technique well and TwPdi provided a nonvolitional measure of diaphiagm 
strength. As mouth pressures are invariably reduced, assessment of TwPdi could provide 
useful information as a daytime measure of nocturnal events in this group of patients 
(Identified 75% of patients with SRBD in the group). This is more likely to be of value 
in patients who perform volitional tests suboptimally. In two normal subjects the tests 
were repeated and the coefficient of variation in TwPdi value was noted to be 8 % in 
between the occasions.
It was of interest to note that the sniff Poes, Pdi and TwPdi values we obtained in normal 
people were slightly lower than expected from other centres where these tests are carried 
out routinely. It was ensured that there was no apparent leak in the system. It is quite 
likely that our normal controls were physiologically at the lower end of ‘normality’ and 
hence the variation. It is known that for human diaphragm the ratio of single twitch to
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maximal contraction is 0.23-0.24(200,201). It did not appear to be related to poor effort, 
as the values were consistent
and reproducible. The small number of subjects studied might have contributed to this 
effect as well.
Sleep studies were quite useful to provide the sleep architecture that could explain the 
disturbed sleep pattern. Only one patient with normal FVC, sniff Pdi and minimally 
reduced Tw Pdi at 17.6 cm H2O had significant nocturnal disturbance in the form of 
central sleep apnoea and awake hypercapnia. His wife had noticed episodes of apnoeas 
prior to participating in the study. It is quite likely that this subject has an abnormal 
respiratory drive or disordred afferent input from the diapluagm that contributed to the 
SRBD. However, diapliragm EMG/respiratory drive was not directly measured in my 
studies. His resting breathing frequency was 16 breaths/min. His VT/Ti as a measure of 
drive was not significantly different to the group [Mean (sd) of 0.390(0.150)l/sec in 
normal subjects to 0.343(0.170)l/sec in MyD group]. There was also no difference in 
Ti/Tot between normal subjects and MyD subjects [0.417(0.062) vs 0.480(0.024) 
respectively].
Peripheral muscle strength
There was no direct correlation between the peripheral muscle strength (as assessed by 
MVC quadriceps) and measures of respiratory muscle strength including TwPdi. This 
suggests that peripheral muscle weakness has no direct relevance to respiratory muscle 
involvement in these patients. However none of the patients we tested had significant
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proximal weakness and our results may well be due to this. Strength was measured in 
only one leg but all the subjects had been examined to ensure that there was no 
asymmetry of power in their legs. Non volitional assessment of strength (electrical or 
magnetic stimulation of the femoral nerve with EMG monitoring) was not carried out and 
hence it is not entirely clear whether MVC underestimates strength in MyD as volitional 
respiratory muscle tests do.
Again high BMI was associated with increased frequency of sleep related breathing 
problems. In future studies it would be interesting to see if weight loss has any impact on 
the nocturnal parameters. Dietary advice should probably be given to overweight MyD 
subjects especially in view of the associated adverse respiratory outcome.
Targeted sleep studies depending on the symptoms may well provide useful information 
in MyD. Certainly patients with multiple symptoms suggestive of respiratory muscle 
weakness, hypoventilation or upper aiiivay collapsibility should be considered for 
nocturnal assessment especially if they are overweight. This is particularly important as 
one patient with near normal TwPdi did have SRBD at the outset. Our experience with 
NIV confirmed the well-recognised poor compliance with treatment in this group of 
patients.
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3.3.6 Conclusions
1. Sniff Pdi taken as the gold standard for diaphragm strength can significantly under­
estimate Pdi in comparison to Tw Pdi assessed by BAMPS.
2. Though FVC correlated well with PaC0 2 , it was not significantly different between 
paitents with SRBD and non SRBD. Tw Pdi, however, correlated well with hypercapnia 
and was a useful to identify MyD patients with SRBD. However, SRBD occuned in 
MyD inspite of both preserved FVC and diaphragm strength. In a symptomatic patient, 
even when TwPdi is normal, sleep studies should be considered for further evaluation.
3. Peripheral muscle strength as assessed by MVC quadriceps did not correlate with 
transdiaphragmatic pressure assessed by BAMPS or general muscle weakness.
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3.4 RESPIRATION IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) 
3.4.1: Hypotheses
1. Serial monitoring of volitional tests of respiratory muscle strength would identify 
patients with SRBD.
2. Sti'ength of correlation between respiratory muscle tests and SRBD is strong.
Our secondary aims were to
1) Define the prevalent symptoms of respiratory muscle weakness in MND.
2) Define the prevalence of bulbar symptoms.
3) Relate ALS- Functional rating scale (ALS-FRS) to respiratory muscle strength 
parameters.
4) To assess non invasive and invasive respiratory muscle strength in MND at an 
interval of 4 months.
3.5.2 Study Design:
1. Obtain written informed consent
2. Eligibility check with particular attention to symptoms and mode of confirmation of 
underlying diagnosis
3. Questionnaires
- Epworth Sleepiness Scale (appendix III, 179)
- ALS-Functional Rating Scale (appendix VIII, 202)
ALS-FRS is a physician generated estimate of the patient’s degree of functional 
impairment and is evaluated by response to 10 questions regarding daily activities. Each
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task is scored on a 5 point scale (0-4) with the sum to produce a score between 0 (worst) 
to 40 (best).
4. Baseline pulmonary function tests -  FEVi, FVC
5. Lying and standing vital capacity
6 . Oxygen Saturation Assessment/ABG
7. Overnight home oximetry
8 . Volitional respiratory muscle strength assessment using MIP, MEP, SNIP and sniff 
transdiaphragmatic pressures.
9. Non-volitional respiratory muscle strength assessment using BAMPS
3.4.3 Results
10 patients with MND participated in this study -  9 males, 1 female. All the 10 subjects 
had been commenced on riluzole. Mean age was 57.2(16.9) years.
Main symptom of refeinal included breathlessness (75%, 1/3'^ of these subjects had 
orthopnoea), tiredness (50%), morning headache (20%). 33.3% of the patients studied 
had symptoms suggestive of bulbar involvement. Table 3.4.3.1 summarises the 
differences in baseline characteristics between visits I and II. One subject had died in the 
interim and one did not wish to come for the second visit in view of worsened mobility. 
There was significant weight loss within the group after 4 months of initial assessment. 
The prevalence of mood disturbances was higher during the II visit and the functional 
impairment more marked.
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Table 3.4.3.1: Differences between I and II visits in baseline characteristics.
I Visit
II = 10
II Visit 
n = 8
Body Mass Index (kg/m^) 25.0(5.0) 21.4(3.6)*
ESS 5.2(1.5) 6.4(1.6 )
HAD “ Depression 8.5 (2.9) 11.4(3.6)*
HAD - Anxiety 11.2 (3.4) 12.6 (3.2)
ALS -  FRS score 36.2(2.8) 30.8(4.0)*
*p < 0.05
Pulmonary function tests:
There was one former cigarette smoker in the group. None of the subjects had 
obstructive spirometry at the outset. Either the values were normal or represented 
restriction in keeping with underlying respiratory muscle weakness. The percent fall in 
supine vital capacity was minimal even in the face of marked reduction in mouth 
pressures at 4.6(4.0) during the first visit and 10.6(6.2) at the second visit.
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Fig 3.4.3.1: Basic spirometry between visits I and II.
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Fig 3.4.3.2: Summary of volitional respiratory muscle strength between the 2 visits.
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The decline in MIP, SNIP and Peak MEP with time was statistically significant. 
However all the parameters showed decline suggesting progressive respiratory muscle 
weakness. The decline in body mass index during that time would have contributed to 
the reduction in mouth pressures in part. Patients with lower ALS -  FRS scores showed 
greater reductions in mouth pressures (r—-0.4 MIP vs ALS-FRS score). However this 
was not statistically significant.
Three subjects undeiwent invasive respiratory muscle strength assessment and only two 
agreed for the repeat tests. None of these subjects had bulbar symptoms. In general, 
BAMPS confirmed severe diaphragmatic weakness in all the three subjects with further 
decline in the strength on repeat tests.
Mean MIP was 30.3(11.4), MEP 49.7(17.8) and SNP 29.8(15.8) for these 3 subjects. 
Sniff Poes was 28.0 (11.5), mean sniff Pdi 36(6.5) suggesting severe inspiratory muscle 
weakness. Bilateral TwPdi was also reduced to 5.5 (2.2) cm H2O in keeping with severe 
diapliragm weakness. Again it was interesting to note that there was no significant 
correlation between percent supine fall in VC and TwPdi. Cough Pgas was also reduced 
with mean level of 46.3(19.5) H2 O suggesting significant expiratory muscle weakness.
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Sleep and Arterial Blood Gas assessment:
All the subjects had overnight oximetry and arterial blood gas assessment during the 
daytime. Overnight oximetry showed mean SpOg level to be 90.6(4.2), Desaturation 
index was 16.2(9.6). Correlation between DI and FVC was non significant (i--0.4). 
Mean PaOa for the group was 8.4(3.2) and PaCOz of 7.1(2,2). Though there was no 
significant correaltion between DI and mouth pressures, SNIP showed a trend towards 
significance when compared with time spent below SpO] of 90% (r—0.7, p=0.048). Five 
subjects had daytime hypercapnia with established respiratory failure. Correlation 
between FVC and PaC0 2  was good (i-0.7, p=0.02).
PaC02 vs Bicarbonate level
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Fig 3.4.3.3: Conelation between PaCOz and bicarbonate level compared to MyD subjects 
from section 3.3. The conelation was higher in MND patients compared to MyD [1-O.6 , 
p-0.048; R^=0.661, p=0.038 in MyD group compared to 1-0.917, p=0.00; R^=0.835, 
p-0.003 in MND group]. The correlation between the two variables was high for the 
group [i-0.867(p-0.00), R^-0.769(p=0.00)].
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When all the variables were considered in combination (Tw Pdi not included due to small 
numbers), PaCOi was best explained by % FVC, SNIP and Peak MEP (p=0.06). It is 
quite likely that this failed to reach statistical significance due to the sample size.
3.4.4 Experience with NIV in the MND group
Six subjects were commenced on NIV following the initial assessment (5 had 
hypercapnie respiratory failure and 1 subject had severe nocturnal desaturation on 
oximetry). They all had NIV trial in hospital for at least one night. One opted not to 
continue with the treatment. This subject had severe respiratory muscle weakness 
without daytime hypercapnia and was commenced on NIV in view of symptoms and 
oximetry findings. Table 3.4.4.1 gives a summary of ABG pre and post NIV (overnight).
Table 3.4.4.1: ABG pre and post NIV.
Pre NIV (n = 6) Post NIV (n = 5)
PaOz 7.6(2.8) 9.0(2.2)*
PaCCb 7.1(1.9) 6 .1 (2 .1 )
HCO3-' 32.5(2.5) 33.1(2.8)
H+ 43.3(5.3) 42.6(3.8)
*p<0.05
At 4 weeks review, all NIV users noted symptomatic benefit. 2  subjects were using it for 
15-18hours a day and 3 were using NIV overnight. Commonest problem was related to 
the mask. Interestingly we noted that all the patients required low inspiratory and 
expiratory positive airway pressures with mean IPAP of 10cm H2O and EPAP of 6  cm 
H2O. This was in contrast to 10 historical controls established on BIPAP with mean 
IPAP of 15.1(2.9) and EPAP of 9.5(2.7) cm H2O.
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3.4.5 Discussion
Patients with MND had more pronounced symptoms of respiratory muscle weakness at 
presentation and the weakness progressed rapidly in contrast to MyD patients during II 
visit. The symptomatic benefit with NIV was quite marked. However in this set of 
patients expiratory aids were not offered and routine measurement of peak cough 
expiratory flows was not carried out.
Respiratory muscle strength assessment revealed reduced mouth pressures and SNIP with 
rapid decline in both patients who went on to develop respiratory failure during the study 
period and those who did not (only one subject during the second visit at 4 months). 
Mortality within the group was also high with half of them succumbing to the disease in 
the 6  months of follow up. There was no significant difference in the rate of decline 
between patients who went on to NIV and those who didn’t. Our sample size is small to 
assess this effect. Patients with bulbar symptoms did show the lowest SNIP values. 
Again due to the sample size, no clear conclusions can be drawn about the differences 
between bulbar group and those with predominantly limb involvement.
Basic spirometry, SNIP, overnight oximetry provided useful initial assessment tools for 
this group of patients. There is evidence on SNIP to predict survival (203) and hence its 
routine monitoring would be able to predict onset of SRBD. All the patients with FVC < 
50% at the outset in our group went on to develop respiratory failure within 6  months. 
BAMPS was useful to provide quantitative diaphragm strength in this group of patients.
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However it did not add any useful information for routine monitoring of these patients. 
Small sample size could have attributed to this result. In contrast to MyD patients, 
symptoms of respiratory muscle weakness and/or hypoventilation were more marked in 
MND patients and this was also useful marker of underlying SRBD.
It was interesting to note that inspite of significant weakness of global respiratory as well 
as diapliragm weakness, the fall in supine vital capacity was not high as could be 
expected. Certainly it was greatest in the patient with lowest Tw Pdi. This is again 
discussed in detail in section 5.1.
Since upper airway collapsibility is not a constant feature of MND, multi channel sleep 
studies are unlikely to be useful for routine clinical care. In our experience, overnight 
oximetry at home was welcomed by all the patients and provided infoiination regarding 
overnight mean oxygen saturation and desaturation index that would guide further 
management.
3.4.6 Conclusions:
1. Our subject group was polysymptomatic for nocturnal hypoventilation with severe 
respiratoy muscle weakness even at the outset and this showed rapid significant decline 
on repeat testing at 4 months.
2. SNIP showed strong correlation with time spent below Sp0 2  < 90%. There was no 
significant correlation between mouth pressures and DI.
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DATA HANDLING AND STATISTICAL ANALYSIS
All the data were stored on a computer in keeping with data protection act. Statistical 
analysis was carried out using a statistical software package (SPSS 14.0, SPSS Inc, 
Chicago, USA). Statistical significance was defined as p<0.05. Non-parametric statistics 
(Mann Whitney-U test) were used to compare the data between two groups. For 
variables measured in the same gi'oup on two occasions, Wilcoxon signed-rank test was 
used.
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I set out to explore the various methods of assessing respiratory muscle strength and 
identify predictors of ventilatory failui'e in neuromuscular diseases as daytime 
hypercapnia is a late event and tests that could predict onset of respiratory failure would 
be useful in day to day clinical practice. The degree of respiratory muscle weakness and 
its contribution to ventilatory failure is variable amongst different neuromuscular 
diseases. Hence interpreting different pulmonary function variables, mouth pressures, 
blood gas parameters in light of symptoms will be necessary to plan management in 
individual patient setting. Myotonic dystrophy and Motor neurone disease patients were 
studied in my research.
5.1 Critique of methods used 
Subject selection:
It would have been ideal to study the full lung function tests, volitional tests of 
respiratory muscle strength, sleep studies followed by nonvolitional tests in a proportion 
of patients. Given the complexity of the disease studied, MyD and a rapidly progressive 
primary neurological disorder, MND, this did not turn out to be practical. Hence, patients 
who participated in the sleep studies subsection were different to the ones who consented 
to undergo the invasive tests. Studying more number of patients in MND group would 
have strengthened the data but again this did not prove to be practical.
Questionnaires:
ESS was originally developed for assessment of patients with primary sleep disorders 
(181) such as sleep apnoea and narcolepsy. It was not intended for primary assessment of
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NMD patients. However it gives a very good indication of subjective sleepiness and has 
been shown to decrease after the initiation of NIV correlating with improvement in 
symptoms. Hence I used ESS in my studies. Though in the original study ESS score of > 
14 is considered significant, there are studies which have shown that patients are 
symptomatic even when it is lower. ESS >11 has conventionally been used in our lab 
and this thieshold was maintained throughout my studies.
Sleep Monitoring:
Overnight sleep studies have many problems on their own. Patients may not sleep well in 
the sleep lab and that would alter results obtained. Transcutaneous CO2 analysis would 
have added in further information and given a clearer idea about nocturnal 
hypoventilation in our patients. However, this should not undermine the results of the 
current study as significant numbers of patients with SRBD (50% in PSG group and 
36.8% in the overnight oximetry group studied) were picked up.
Volitional Respiratory Muscle strength:
It was obseiwed that volitional muscle strength obtained for our cohort of subjects was 
lower compared to that reported in the literature (appendix I, II). Reasons for this are 
discussed in Section 3.3.5. Criteria for measurement was in accordance with other 
studies and great care was taken to ensure maximality of the procedure with constant 
verbal and visual encouragement to subjects. Also, it was ensured that SNIP and sniff 
Poes pressure tracings were identical during sniff Pdi manoeuvres. In view of this, 
absolute values of the mouth pressures, SNIP and sniff Pdi were used for analysis rather
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than percent predicted values used in literature. Non-invasive measures of expiratory 
muscle strength such as peak cough expiratory flow rate was not evaluated in my studies 
and certainly this should be considered in clinical management of neuromuscular disease 
patients especially in view of emerging evidence of benefits of in-exsufflators.
Supine Vital Capacity
It was suiprising that large falls in supine vital capacity (>20%) was a rarity in our 
subjects even when the Tw Pdi was low considering reported direct relation between fall 
in VC and nocturnal desaturation (97). Within the MyD group, percent fall in supine VC 
was 12.6(9.1) in SRBD group, compared to a fail of 6.2(4.9)% in the non-SRBD. 
Excluding the subject with SRBD who had normal FVC, the values for fall in supine VC 
were 12.3, 17, 21% which would be expected given the low TwPdi. Within the MND 
group, % fall in supine VC was rather low given the severity of diaphragm weakness at 
4.6(4.0)% but this incremented to 10.6(6.2)% at the second visit as the weakness 
progressed. A contributing factor could be the altered diapliragm force-length 
relationship in supine position in our subjects. Certainly none of them had visible chest 
wall deformity that could explain this. Abdominal muscles prevent diaphragm to over- 
shoiten during contraction and increased activity of these muscles has been shown in 
MyD. It is quite likely that this again altered the force-length relationship in the supine 
posture and contributed to our results. FVC estimates global respiratory effort and rib 
cage muscle contribution was not separately assessed in my studies. As supine VC is a 
relatively insensitive marker for diapln agm strength (though specific ie., if present highly 
suggestive of diaphragm weakness), it is quite likely that our group of patients had good
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‘extra-diaphragmatic inspiratory muscle strength’ even when the Tw Pdi was low 
preventing supine fall in VC. Smaller size sample could also have prevented the 
differences from emerging.
Tw Pdi measurements:
BAMPS has been shown to be supramaximal for Tw Pdi assessment. This was 
confirmed in our lab in two nonnal subjects by varying the intensity of the Magstim 
stimulator output. Diaphragm EMG as an indicator of ‘motor output’ was not assessed 
in my studies. No evidence of myotonia was picked up during the study time in MyD 
group and hence it is unlikely to have contributed to the ventilatory impairment in our 
group of subjects.
Another potential problem in TwPdi measurement is that due to obesity especially in 
MyD which increases the abdominal girth. This in turn increases the impedance of 
abdomen and rib cage giving a higher Pdi measurement. Also, as baseline diapliragm 
activity can be high, twitch potentiation is a possibility and hence all the waveforms were 
visualised prior to analysis.
Peripheral muscle strength assessment:
As motor involvement in MND can be patchy, quadriceps strength was not assessed. 
MVC quadriceps values measured in the dominant leg were found to have no correlation 
to general muscle weakness as assessed by MDRS or diaphragm strength assessed by
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TwPdi. However, nonvolitional measures of peripheral muscle strength were not used in 
my study.
5,2 Final Conclusions:
Pulmonary function tests in Myotonic dystrophy and Motor neurone disease:
Of all the routine pulmonary functions tests, basic spirometry still provides most useful 
information at the outset. This has to be supplemented with mouth pressures to identify 
subjects with respiratory muscle weakness in MyD and MND with 56% of those studied 
showing significant reduction in both spirometric values and mouth pressures.
Sleep studies in MyD and MND:
Screening sleep studies were useful to identify 12% of MyD subjects who would have 
been missed on routine spirometry and mouth pressures alone. Their targeted use in 
MyD patients particularly those with multiple symptoms of respiratory muscle 
weakness/nocturnal hypoventilation, who are overweight would help to pick up SRBD. 
Symptoms of respiratory muscle weakness (orthopnoea, morning headaches in particular) 
within MND group invariably revealed significant SRBD on overnight monitoring.
Volitioanl and Non volitional tests in MyD and MND:
We describe BAMPS as a useful teclinique to assess nonvolitional diaphragm strength in 
MyD for the first time. This also seems to be a daytime marker of SRBD in 75% (MyD 
group). Respiratory muscle weakness progression in MND is rapid with progressive 
symptoms and close monitoring of these patients will be needed. MyD subjects on the 
other hand, had stable muscle strength both by volitional and nonvolitonal methods after
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6  months. No new symptoms of SRBD were reported at the second visit, when these 
tests remained stable.
Main conclusions in MyD:
■ On linear regresssion, Tw Pdi and % predicted FVC proved to be the main 
predictors for daytime hypercapnia (p=0.019). Tw Pdi should be considered in 
patients with low volitional respiratory muscle strength.
■ The positive predictive value of FVC<60% predicting SRBD (sensitivity) was 
67% and specificity ie., >60% excluding SRBD was 85%. Hence these 
physiological tests should be interpreted in the light of symptoms as SRBD was 
seen with normal FVC, sniff Pdi and mildly reduced Tw Pdi. Further tests in the 
form of sleep studies and assessment of drive should be considered in this 
instance.
■ On repeat tests at 6 months, both volitional and nonvolitional tests were stable and 
this is reassuring at a clinical level, where MyD patients can be monitored with 
volitional tests for respriratory muscle strength if TwPdi at the initial visit is in the 
normal range.
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Main conclusions in MND:
■ Best correlates for hypercapnia in MND group were % FVC, SNIP and peak 
MEP, though just outside the level of significance (p=0.06) which is likely to be a 
reflection of the sample size.
■ Serial monitoring is more crucial as respiratory muscle weakness progression was 
rapid. SNIP correlated with nocturnal desturation.
■ Strong correlation between bicarbonate level and PaCOi strengthens the evidence 
for home monitoring patients with respiratory failure due to MND (146).
5.3 Future directions:
We hope to have added further insight into the physiology of respiration in MyD and 
MND. It has been shown that BAMPS can be used to dissociate upper airway muscles 
from the contraction of diaphragm (204). This has proved to be a useful technique to 
study upper airway dynamics in patients with sleep apnoea hypopnoea syndrome and 
assess response to continuous positive airway pressure therapy (205,206). Since it is well 
known that upper airway collapsibility occurs in MyD, feasibility of BAMPS opens up 
interesting avenues to study these patients during the daytime to gain insight into 
nocturnal events. This is especially important given the complexity of sleep studies, the 
behavioural aspects of MyD patients and their general unwillingness to seek medical 
attention or comply with treatment. Home monitoring with venous bicarbonate, given the 
correlation with PaCOi is another aspect that is worth exploring in these patients as is 
studying respiratory drive along with nonvolitional measures of diaphragm strength.
172
Due to the small number of patients that require specialised respiratory assessment it may 
be useful to identify regional centres which have expertise in carrying out both volitional 
and nonvolitional techniques of respiratory muscle strength assessment and provide 
useful advice on any problems encountered with non-invasive ventilation in the region. 
Certainly as in conditions such as chronic obstructive lung disease, home assessments 
including spirometry and sleep studies can be brought into practice and some of my 
studies have certainly shown the feasibility of these tests at home. A close collaboration 
between various specialists is paramount for the good clinical care needed for these 
patients including neurologists, medical geneticists, specialist nurses, physiotherapist, 
social worker, carer and the respiratory physicians. I do sincerely hope that all my work 
over the last 3 years has provided a foundation for a functional Scottish Neuro 
Respiratory Assessment centre in Glasgow with continued collaboration between the 
specialists.
I would like to conclude this thesis by providing a summary sheet that we found usefril 
for the initial assessment and follow up of neuromuscular disease patients. This is 
currently being utilised at the respiratory laboratory in Gartnavel General Hosptial.
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Neuromuscular Disease Assessment, Respiratory Unit, Gartnavel General Hospital 
Diagnosis:
Duration:
Past History: Smoking: yes/no/ex
Medications:
Duration:Symptoms of Inspiratory muscle weakness:
Breathlessness □
Orthopnoea □
Easy fatigability □
Excessive daytime sleepiness □
Choking at night □
Snoring □
Disturbed sleep □
Witnessed apnoea □
Morning headache □
Cough □
Symptoms of Expiratory muscle weakness/bulbar symptoms:
Recurrent chest infections □
Inability to clear secretions/cough □
Associated symptoms:
Swallowing Difficulty □
Wt Loss □
Speech problems □
Limitation of mobility □
Examination: (INITIAL VISIT)
Wasted respiratory muscles □
Accessory muscle use □
Paradoxical abdominal motion □
Normal chest expansion □
Additional sounds □
Ht: Wt: BMI: Epworth Sleepiness Scale: SpOz:
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Value (L) % predicted Supine value (L) %supine fall (VC)
FEVl
FVC
(> 25% fall in supine VC is strong evidence for diaphragm weakness -  arrange sleep 
studies even if other indices normal)
Value Normal values
MIP (maximal inspiratory pressure) >80 cm H2O
MEP (maximal expiratory pressure) >90 cm H2O
SNIP (sniff nasal inspiratory pressure) >70 cm H2O
Peak cough flow rate >3L/sec (PEER on the spiro)
ABG (if FVC < 50% predicted, symptoms of hypoventilation)
(non volitional diaphragm strength assessment to be considered if accurate diaphragm 
strength is sought and mouth pressures are low due to facial weakness)
Sleep Studies: (if FVC < 50%, symptoms of hypoventilation and Pa0 2  >10, PaC0 2  < 6  
kPa)
The current practice has been to obtain spirometry, mouth pressures a day prior to the 
clinic visit and if needed, overnight oximetry kit will be issued. If Rirther sleep study 
(polysomnography) or full PFT (Eg., associated airflow obstmction or diffuse lung 
disease) is thought to be useful during the clinic visit, these will be organised as an 
outpatient.
Follow up: 6-12 months (stable patients)
3/12 (If respiratory muscle weakness progression unclear at the outset)
1-2/12 (Motor neurone disease/rapidly progressive muscle weakness on NIV)
Facilities available for self referral if symptoms develop, for early assessment and 
management.
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III- Epworth Sleepiness Scale
The Epworth Sleepiness Scale is used to determine the level of daytime sleepiness. Use 
the following scale to choose the most appropriate number for each situation.
0  = would never doze or sleep.
1 = slight chance of dozing or sleeping
2  = moderate chance of dozing or sleeping
3 = high chance of dozing or sleeping
Situation Chance o f Dozing or Sleeping
Sitting and reading________________________________ ____
Watching TV ____
Sitting inactive in a public place_____________________ ____
Being a passenger in a motor vehicle for an 
hour or more
Lying down in the afternoon ____
Sitting and talking to someone_______________________ ____
Sitting quietly after lunch (no alcohol)
Stopped for a few minutes in traffic 
while driving
Total score
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IV
THE SHORT FORM 36 HEALTH SURVEY 
QUESTIONHAIRE (SF-36^) ' ‘
The folipwing qpestionj ask for your views about your health, how you feel and how well 
you are able to âô your usual activities. If you are unsure about how to answer any questions 
please give the best answer you can and make any of your own comments if you like. Do not 
spend too much time in answering as your immediate response is likely to be the most accurate.
In generat, would you say your health is:
{Please tick one box)
Excellent 1— 1
Very good ruii>Li|i|,i,iMnuw*jl
Good
Fair
Poor m
2. Compared to one year ago, how would you rate your health in general now?
(Please tick one box)
Much better than one year ago [   |
Somewhat better than one year ago p™'"""'""]
About the same 
Somewhat worse now than one year ago
Much worse now than one year ago 1 IWi fj (* In ■WlMJfHI
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3. HEALTH AND DAE.Y ACTIVITIES
a)
b)
c)
d)
e)
f) 
B) 
h) 
î) 
j)
The following quêtions are about activtte you Aight db düfini à typical dayriJodà your health limit you in these activities? If so, how much?
(Phase tick cm  box on each line)
Vtgoroiis activities, sueh as tunningj lifting heavy objects, 
participating in strenuous sports
Moderate activities, such as moving a table, pushing a 
vacuum, bowling or playing golf
Lifting or carrying groceries
Climbing several flights of stairs
Glimbing one flight of stairs
Bending, kneeling or stooping
Walking more #an  # mile
Walking half a mile
Walking 100 yards
Bathing and dressing yourself
Yes,
m i w
é m i w m«lîtfle
No, not 
TimiWdm m:cn
n u  n n  c n
aCZ3
a
C 3  n u  U 3
□ ] CZD 
CZ3
d ]
CZ3 O  □
4.
a)
b)
c)
d)
During the past 4 weeks, have you had any of the Mlowihg problems with your 
work er other regular daily activities as a result of your physlcatl health?
(Please answer yes or No to each (jaestion)
Yes
Cut down on the amount of time you spent 
on work or other aotivities
Accomplished Im  than you would like
Were limited in the kind of work or other activities
Had difficulty performing the work or other 
activities (eg it took more effort)
O
No
CZ]
□
] C Z
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5, During the past 4 weeks, have you had any of tlie following problems with your
work or other regular daily activities as a  result of any emoitional prohiénus (such as 
feeling depressed or anxious)?
(Please answer o r  N n %  eocA qaestion)
a) Cut down on tiie am ount of time you spent on work or
other aotivities
b)
e)
Yes No
Accomplished less than you Would like
Didn't do work or other activities às carefully as usual |..... |
6- During the past 4 weeks, to what extent have your physical health or emotional problems
interfered wtthfyour normal social activities with familyt Mends, neighbours or groups?
(Please tick one box)
Not at all I I
Slightly fc. iMti |* mi
Moderately [~ I■iw»n«mimii|ini nf. I'l!
Quite a bit I IIwWlWWWflHWWwiil
Extremely
7, How much bodily pain  have you had during the past 4 weeks?
(Plêqse tick one box) 
Non& I I
VmymUd |--------1
Mild I........ ; :
Moderate f 1
Severe j" ^~"j|
Very Severe [ |
During the past 4 weeks how much didipalin interfere with your normal work (including work 
both Outside the home and housework)?
(Please tick one box)
Not at all 
A little bit 
Moderately 
Quite a bit 
Extremely
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YOUR FEELINGS
9.
a)
b)
c)
d)
e)
f)
g)
h)
i) 
j)
These questions are about ho* you feel and how things havO been with you 
dttrihg (he pMtntoiith. (For eich qnéi t^ion, please indicate the one 
answer that comes closest to the way you have been feeling).
(Phase tick om  box on each line)
How much time during 
the last month;
Did you feel full of life?
Have you been a very nervous 
person?
Have you felt so down in the 
dumps that nothing could cheer ydu
up?
Have you felt calm and peaceful?
Did you have a lot of energy?
Have you felt downhearted and 
low?
All
of the 
time
Most 
of the 
time
Has your health limited ybub 
social activities (like visiting 
friends or close relatives)?
A good 
bit of 
the time
Some 
of the 
timeCZ3
Did you feel worn out? J
Have you been a happy person? I * I I ^
Did you feel tired? j........ ' '"'j I 1'^"1" .
CZ
A  little 
of the 
time
None 
of the 
time
a  C Z
CZCZ
HEALTH IN GENERAL
10.
a)
b) 
o)
d)
PleaseichoosO the answer that best describes how true or false each of the 
following statements is ("or you.
(Please tick one box on each Htte)
Definitely Mostly 
true true
I seem to get ill more easily than Other
people
I am as healthy as anybody I know 
I expect my health to get worse 
My health is excellent CZ CZ
Not
sure
Mostly Definitely 
false false
] CZ ] CZ
SP36 is a trade mark of the Medical Outcomes trust
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V - Muscular Disability Rating Scale
0 - No clinical impairment
1 -  Minimal signs of weakness (ptosis, myotonia, facial or neck flexor weakness)
2 -  Distal weakness (Weakness of muscles distal to extensors at elbow)
3 -  Moderate proximal weakness (Grade 3/5, 4/5 motor power)
4 -  Non ambulatory (Grade < -3/5 motor power)
This has been tested for interrater reliability which is good. It is not recommended for 
use in short term therpeutic trials.
VI -  HAD Scale -  Scoring sheet
207
Ï feel tense or "wound wp": A
Most o f  the time 3
A lot o f  the time 2
Time to time, occasionally 1
Not at all 0
I stJIienJoy the things I  used to: D
Definitely as much 0
Not quite as much 1
Only a little 2
Hardly at all 3
I get a sort of frightened feding as if  A
something bad is  «bout to hapj^n;
Vcry dcfmiteiy and quite badly 3
Yes, Imt not too badly 2
A  little, imt it  docsn’t wony me 1
Not at all 0
I can laugh and see the funny Adè df things; D
As much as I ever coiild 0
Not ipite as much how 1
DcQhitely not as much 2
Not at all 3
I  feel as if  1 am slowed down: D
Nearly all the time 3
Very often 2
Sometimes 1
Not at all 0
I  get a sort o f frightened feeling like 
"butterflies" in the stomach: A
Not at all 0
Occasionally 1
Quite often 2
Very often 3
I have lost interest In ray appearance; D
Definitely 3
I <k)n’t t& e as imgîh cat^ s as I slmtid 2
i  may not take quite as much care I
I take just as m u #  etfte asT ever did 0
I feel restless as if  1 have to be on the move: A
Very much indeed 3
Quite a lot 2
Not very much 1
Not at all 0
Worrying thoughts go tbrongh my mind: A  
A  great deal of the time 3
A lo t of the time 2
From tfanë to time, not too often 1
V ,  Only occasionally
I feel checribl:
Not at all 
Not often 
Sometimes 
Most o f the time
0
I look forward with enjoyment to things;
As much as I ever did 
Rather le ^  than 1 used to 
Deftniteiy less than 1 u s #  to 
H ar^yatall
Ï get fttdden feelings o f panic: A
Very Often indeed 3
Quite often 2
Not vetj'often 1
Not at mi 0
I  can idt and fe d  relaxed:
Definitely 
Usually 
Not often 
Not at all
I  can enjoy a good book or TV Or 
Radio Programme:
Often 
Sometimes 
Not often 
Very seldom
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VII -  Myotonie Dystrophy Care Card
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VIII - ALS Functional Rating Scale
A. Speech
4 - Normal speech processes
3 - Detectable speech disturbances
2 - Intelligible with repeating
1 - Speech combined with nonvocal communication
0 - Loss of useful speech
B. Salivation
4 - Normal
3 - Slight but definite excess of saliva in mouth; may have night time drooling
2 - Moderately excessive saliva; may have minimal drooling
1 - Marked excess of saliva with some drooling
0 - Marked drooling; requires constant tissue or handkerchief
C. Swallowing
4 - Normal eating habits
3 - Early eating problems - occasional choking
2 - Dietary consistency changes
1 - Needs supplemental tube feeding
0 - NPO (exclusively parenteral or enteral feeding)
D. Handwriting
4 - Normal
3 - Slow or sloppy; all words are legible
2 - Not all words are legible
1 - Able to grip pen but unable to write
210
0 - Unable to grip pen
E. Cutting Food and Handling Utensils
(patients without gastrostomy-feeding tube)
4 - Normal
3 - Somewhat slow and clumsy, but no help needed
2 - Can cut most foods, although clumsy and slow; some help needed
1 - Food must be cut by someone, but can still feed slowly
0 - Needs to be fed
Cutting Food and Handling Utensils(altemate scale for patients with gastrostomy)
4 - Nonnal
3 - Clumsy but able to perform all manipulations independently
2 - Some help needed with closures and fasteners
1 - Provides minimal assistance to caregiver
0 - Unable to perform any aspect of task
F. Dressing and Hygiene
4 - Normal function
3 - Independent and complete self-care with effort of decreased efficiency
2 - Intermittent assistance or substitute methods
1 - Needs attendant for self-care 
0 - Total dependence
G. Turning in Bed and Adjusting Bed Clothes
4 - Normal
211
3 - Somewhat slow and clumsy, but no help needed
2 - Can turn alone or adjust sheets, but with great difficulty
1 - Can initiate, but not turn or adjust sheets alone
0 - Helpless
H. Walking
4 - Normal _
3 - Early ambulation difficulties
2 - Walks with assistance
1 - Nonambulatory functional movement
0 - No purposeful leg movement
I. Climbing Stairs
4 - Normal
3 - Slow
2 - Mild unsteadiness or fatigue
1 - Needs assistance
0 - Cannot do
J. Breathing
4 - Normal
3 - Shortness of breath with minimal exertion (e.g. walking, talking)
2 - Shortness of breath at rest
1 - Intermittent (e.g. nocturnal) ventilatory assistance 
0 - Ventilator dependent
UNIVERSITY
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